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Deleted in Liver Cancer-1 (DLC1) is a multi-modular Rho GTPase-activating 
Protein (RhoGAP) and a tumor suppressor. In this study, the identification of eukaryotic 
elongation factor-1A1 (EF1A1) and BNIP-2 similar isoform alpha (BNIP-Sα) as two 
novel interacting partners of DLC1, the molecular mechanism and the functional 
significance of the interaction between EF1A1 and DLC1 will be presented.  
DLC1 harbors 3 distinctive domains, i.e. the Sterile-Alpha Motif (SAM) at its 
N-terminus, the Steroidogenic Acute Regulatory-related Lipid Transfer (START) domain 
at the C-terminus and a conserved RhoGAP (GAP) domain close to the middle of the 
protein. Besides its RhoGAP domain, functions of other domains in DLC1 remain largely 
unknown. In my current study, EF1A1 was identified as a novel binding partner of 
DLC1-SAM domain by protein precipitation and mass spectrometry. Residues F38 and 
L39 within a hydrophobic patch on DLC1-SAM domain were identified as an 
indispensable EF1A1-interacting motif. DLC1-SAM recruits EF1A1 to membrane 
periphery and ruffles which plays an auxiliary role in DLC1’s function in cell motility 
suppression. My current study also presents the novel interacting activity between the 
BNIP-2 and Cdc42GAP homology (BCH) domain of BNIP-Sα and DLC1. Three 
BNIP-Sα-interacting regions on DLC1 were delineated, including the START domain and 
two N-terminus regions between the SAM domain and the GAP domain. These findings 
shed light on the mechanisms of how other motifs of DLC1 cooperate with the RhoGAP 
activity to modulate DLC1’s function in cell dynamic control. 
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1.1 Rho GTPase family 
Ras homologous (Rho) GTPases comprise a family of small guanosine triphosphatases 
(GTPases), which belong to the Ras GTPases monomeric G protein superfamily. To date, 
more than 20 members of Rho GTPases have been identified in humans (Wennerberg et 
al., 2005). Based on their primary sequences and known functions, Rho GTPases can be 
roughly divided into 5 groups, the Rho-like, Rac-like, Cdc42-like, Rnd, and RhoBTB 
subfamilies (Figure 1.1) (Burridge and Wennerberg, 2004). RhoA, Rac1, and Cdc42 are 
the three best studied Rho GTPases (Hall, 2005). The following parts in the introduction 




Figure 1.1 20 Rho GTPases can be divided into five subfamilies, Rho-like, Rnd, 
Cdc42-like, Rac-like, and RhoBTB. (Adapted from Burridge and Wennerberg, 2004.) 
 
1.1.1 The Rho GTPase cycle  
1.1.1.1 Mechanism of the Rho GTPase cycle 
Each Rho GTPase contains one conserved G domain of around 20kDa, which 
can bind to GDP/GTP. With their G-domains, Rho GTPases can cycle between active 
GTP-bound state and inactive GDP-bound state like binary molecular switches (Figure 
1.2) (Vetter and Wittinghofer, 2001).  
RhoGTPases bind to GDP/GTP with a common biochemical mechanism. The 
G-domain of Rho GTPases folds into a conserved α/β structure forming a shallow surface 
pocket that accommodates guanine nucleotide (Scheffzek and Ahmadian, 2005). The 
binding to guanine nucleotide involves three regions in the G domain, including Switch I 
region, Switch II region and P-loop. Switch I and II regions contact γ-phosphate directly 
in the GTP-bound state, which results in considerable conformational difference of the 
G-domain compared to the GDP-bound state. Such conformational difference in the 
active state of Rho GTPases can be recognized by down-stream effectors, which only 
bind to and are activated by the active Rho GTPases. The G domain also has intrinsic 
GTPase ability to hydrolyze the bound GTP into GDP. But this intrinsic reaction is very 
slow. After the GTP hydrolysis, Rho GTPases return to the inactive state and terminate 
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downstream signaling. To turn back into activited status, the tightly-bound GDP on Rho 
GTPses then has to be released for the exchange of the next GTP (Scheffzek and 
Ahmadian, 2005). 
 
1.1.1.2 Regulators in the RhoGTPase cycle 
The transitions between the two states of Rho GTPases are regulated by three 
types of molecules inside the cell: guanine nucleotide exchange factors (GEFs), GTPase 
activating proteins (GAPs) and guanine nucleotide dissociation inhibitors (GDIs). When 
Rho proteins are in active state, they can interact with downstream effectors and lead to 
cellular effects (Figure 1.2).  
 
Figure 1.2 The Rho GTPase cycle mediates cellular response downstream of 
extracellular stimuli. The cycle is regulated by GEFs, GAPs and GDIs. When Rho 
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GTPases are in active state, they can interact with effectors and lead to cellular response. 
(Adapted from Jaffe and Hall, 2005.) 
 
GEFs are activators of Rho GTPases. In the Rho GTPase cycle, the GDP-GTP 
exchange reaction is the rate limiting step. GEFs catalyze the exchange of GDP for GTP 
by increasing the rate of GDP dissociation from Rho proteins (Erickson and Cerione, 
2004). GEFs activate Rho GTPases upon the stimulation of growth factors and some 
extracellular agents. There are 85 GEFs found in human genome. Since the upregulation 
of many Rho GTPases contributes to oncogenesis, there is no wonder why many GEFs, as 
the activators of Rho proteins, were identified as oncogenes (Hall, 2005). 
RhoGAPs are negative regulators of Rho GTPases. In the active state of Rho 
GTPases, the GTP-hydrolysis by the intrinsic activity of its G-domain is very slow. The 
inactivation of Rho GTPases by RhoGAPs is achieved by stimulating the GTPase activity 
of Rho GTPases and promoting the hydrolysis of bound GTP to GDP.  
GDIs form in complexes with Rho GTPases to regulate their intracellular 
localizations and block their downstream cellular effects (Olofsson, 1999). GDIs conduct 
three kinds of biochemical activities on Rho GTPases to downregulate the biological 
effects of Rho proteins. First, they keep Rho GTPases in inactive states, by inhibiting the 
dissociation of GDP from Rho GTPases and blocking the activation by GEFs. Second, 
GDIs interact with GTP-bound Rho proteins, inhibiting GTP hydrolysis and blocking 
their interaction with downstream effectors. Third, GDIs can regulate the cycling of Rho 
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GTPases between cytosol and membranes where such effectors are located 
(DerMardirossian and Bokoch, 2005).  
 
1.1.2 Cellular functions of Rho GTPases 
Rho GTPases are key regulators down-stream of extracellular-stimuli that 
regulate a diverse set of biological activities, including cytoskeleton organization, vesicle 
transport, cell polarity, cell cycle progression, gene expression, enzymatic activation, 
differentiation and oncogenesis (Etienne-Manneville and Hall, 2002).  
 
1.1.2.1 Rho GTPases are key regulators of actin cytoskeleton 
The first characterized function of Rho GTPases is their regulation on 
cytoskeleton reorganization. Rho GTPases are key regulators of actin cytoskeleton that 
link extracellular signals and cell surface receptors to the dynamic organization of actin 
cytoskeleton. It is well known that Rho regulates the formation of contractile 
actin-myosin filaments to form stress fibers and the assembly of focal adhesion 
complexes in response to lysophosphatidic acid (LPA) or integrin engagement. Rac 
induces actin polymerization that lead to the assembly of a meshwork of actin filaments at 
the cell periphery to form sheet-like lamellipodia and membrane ruffles in response to 
platelet-derived growth factor (PDGF), epidermal growth factor (EGF) or insulin. Cdc42 
triggers actin filament assembly and bundling at the cell periphery to form actin-rich 
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protrusions on the cell surface called filopodia or shorter protrusions call microspikes in 
response to bradykinin and interleukin 1 (IL-1) (Figure 1.3) (Alberts et al., 2002; Hall, 
1998; Nobes and Hall, 1995; Hall, 2005).  
 
Figure 1.3 Roles of Rho, Rac, and Cdc42 in actin cytoskeleton organization. 
Compared with quiescent cells (-), active Rho induces the formation of stress fiber and 
focal adhesion while active Rac and active Cdc42 induce the formation of lamellipodia 
and filopodia respectively. Actin filaments were shown in A, C, E and G and adhesion 
complexes were shown in B, D, F, and H. (Adapted from Hall, 1998.) 
 
1.1.2.2 Rho GTPases in cell adhesion and cell migration control 
Cytoskeleton makes up the framework for eukaryotic cells. Dynamic 
reorganization of cytoskeleton is the basis of many other cellular activities, such as 
vesicle trafficking, cell adhesion, endocytosis, cell migration and morphological changes 
during the process of apoptosis. The key roles of Rho GTPases on cytoskeleton 
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reorganization are closely related to their ability in the regulation of other cellular 
activities coordinate with actin dynamics, including cell adhesion and cell migration. For 
cell adhesion, Rho activity is required in the assembly of integrin-based focal complexes 
in cell attachment to extracellular matrix. Besides, Rho GTPases regulate the formation 
and maintenance of cadherin-based cell-cell adhesion complexes (Hall, 1998; Malliri and 
Collard, 2003). For cell migration, dynamic rearrangement of cytoskeleton provides the 
driving force for migration in animal cells. In this process, actin polymerization and 
filament elongation at the front and actin:myosin filament contraction at the rear are 
required for directed cell migration in vivo, which are controlled by the coordinate 
regulation of Rac, Rho and Cdc42. Active Rac accumulates at the front of migrating cells 
to form lamellipodia and membrane ruffles to push forward the leading edge membrane. 
Rho induces stress fibers and generates contractile forces  at the rear of the cells  to move 
cell body forward. Cdc42 senses the extracellular cues and establishes the cell polarity, 
which determines the localization of active Rac and makes the cell movement directional 
(Jaffe and Hall, 2005). In addition to actin dynamics, Rho GTPases also regulate 
microtubule dynamics involved in cell migration (Malliri and Collard, 2003). 
 
1.1.2.3 Rho GTPases in cell cycle control 
Rho GTPases also play important roles in cell cycle progression. First, they 
contribute to G1 phase progression. Second, Rho GTPases are crutial for the 
reorganization of the microtubule and actin cytoskeletons during M phase (Jaffe and Hall, 
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2005). The importance of Rho GTPases in cell cycle control is further supported by the 
evidence that their activities are essential for Ras-induced cell transformation (Hall, 1998). 
The roles of Rho GTPases in cell cycle control implicate that their deregulation will 
consequently contribute to malignant transformation and cancers (Villalonga and Ridley, 
2006). 
 
1.1.2.4 Rho GTPases in oncogenesis 
Besides the role of Rho GTPases in cell cycle control, their functions in 
cytoskeleton reorganization, cell adhesion, migration and gene expression also contribute 
to oncogenesis. Deregulation of Rho GTPases contributes to the growth, survival and 
invasiveness of tumor cells. There have been many evidences showing aberrant Rho 
signaling or elevated Rho expression in the formation and progression of tumors. Early 
indications of the role of Rho GTPases in oncogenesis came from in vitro transformation 
studies of fibroblasts. Constitutively active Rac1 (V12Rac) and RhoA (V14RhoA) or 
overexpression of Rho proteins were able to transform normal cells (Prendergast et al., 
1995; van Leeuwen et al., 1995). The transforming capacity of Rho GTPases is correlated 
with the fact that they mediate downstream effects of oncogenic Ras activity in tumors 
(Khosravi-Far et al., 1995). It is now clear that Rac signaling is required for oncogenic 
Ras-induced tumorigenesis, in which Rac stimulates cell growth and enhances cell 
survival under cellular stress (Joneson and Bar-Sagi, 1999). More recently, in vivo studies 
using knockout and transgenic mice of various Rho GTPases demonstrated that the 
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deregulation of Rho GTPases contributes to various aspects of oncogenesis besides 
transformation. Rho GTPases affect the process of tumor invasion/metastasis through 
their pivotal roles in cytoskeleton organization, cell-cell adhesion and migration (Malliri 
et al., 2002; Hakem et al., 2005; Cleverley et al., 2000). Furthermore, some Rho proteins, 
such as RhoC and Rac3, are shown to be upregulated in more metastatic cancers 
(Kandpal, 2006). The role of Rho GTPases in oncogenesis has made them promising 
targets for anti-cancer drug research. 
 
1.1.3 The downstream effectors of Rho GTPases 
In the Rho GTPase cycle, binding of GTP induces conformational changes of 
Rho GTPases, after which they can interact with downstream effectors to mediate various 
cellular functions. To date, there are more than 50 effectors identified for Rho, Rac and 
Cdc42, including serine/threonine kinases, tyrosine kinases, lipid kinases, lipases, 
oxidases and scaffold proteins (Jaffe and Hall, 2005). According to their specificity 
towards Rho GTPases and the interaction region homology, they can be divided into two 
groups, effectors targeting RhoA and effectors targeting Cdc42 and Rac.  
 
1.1.3.1 Effectors targeting Rho 
Rho mediates their cellular functions via specific effectors, including 
 9
serine/threonine protein kinases and scaffold proteins (Dvorsky et al., 2004). Rho 
effectors recognizes and binds to active Rho, i.e. Rho in GTP-bound state, through Rho 
binding domains (RBD) within their coiled-coil regions (Bishop and Hall, 2000; Wheeler 
and Ridley, 2004). 
Many effectors of RhoA are implicated in actin reorganization and actin-related 
activities. Among them, mDia and ROCK are the key molecules that mediate 
RhoA-induced stress fiber formation. mDia promotes linear elongation of actin filaments 
at the barbed ends upon activation by RhoA-GTP, while ROCK mediates the 
cross-linking of myosin to actin and leads to the assembly of contractile actin:myosin 
filaments induced by RhoA (Riento and Ridley, 2003; Hall, 2005; Jaffe and Hall, 2005).  
 
1.1.3.2 Effectors of Rac and Cdc42 
Rac and Cdc42 have relatively high (around 70%) sequence identity and they 
have some common effectors. Correspondingly, their effectors contain a common  
15-residue long binding motif to target Rac/Cdc42, which is called Cdc42/Rac-interactive 
binding (CRIB) motif (Hakoshima et al., 2003). The CRIB motif was first identified as a 
consensus Cdc42-binding sequence for the serine/threonine kinase PAK-1 (p21-activated 
kinase 1) and the activated Cdc42-associated tyrosine kinase (ACK) (Bishop and Hall, 
2000). Later study found that the CRIB motif is essential for the interaction of these 
effectors with Cdc42 or Rac and it only recognizes GTP-bound Rac/Cdc42. So through 
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the CRIB motifs, effectors are able to mediate downstream effects of activated 
Rac/Cdc42. 
Currently, several CRIB-motif containing proteins have been identified. Among 
these effectors, PAKs and the Wiskott-Aldrich syndrome protein (WASP) are the best 
studied. PAK kinases can interact with Cdc42 and Rac, and mediate the activation of 
c-JUN kinase and p38 MAP kinase. PAKs also link Cdc42 and Rac to cytoskeletal 
components such as myosin light chain kinase, which are involved in Cdc42/Rac-induced 
cytoskeleton rearrangements and cell migration (Hoffman and Cerione, 2000). WASP 
directly interacts with actin-related protein 2/3 (Arp2/3) to promote the branched actin 
polymerization and leads to filopodia formation induced by Cdc42 (Millard et al., 2004).  
 
1.2 The RhoGAP family 
1.2.1 Structural mechanism of the Rho GTPase-downregulation by RhoGAPs 
The RhoGAP family is defined by the presence of a conserved RhoGAP domain 
in the primary sequence that consists of about 150 amino acids and shares at least 20% 
sequence identity with other family members (Moon and Zheng, 2003).  
The RhoGAP domain consists of nine alpha helices. A highly conserved arginine 
residue is presented in a loop structure (Moon and Zheng, 2003). The conserved arginine 
residue is essential for the GAP activity and is generally called as “Arginine finger”. In 
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RhoGAP-stimulating GTP hydrolysis, the long side chain of this arginine residue allows 
it to “dip” like a finger into the GTP-binding pocket of G-domain and to stabilize the 
negative-charged core during the transition state of GTP hydrolysis with its positively 
charged guanidinium group. The significance of this Arginine finger has been further 
confirmed by mutational approaches. Mutation of this arginine residue into alanine or 
lysine greatly decreases the GAP activity of most RhoGAPs though they maintain binding 
capacity towards their target Rho GTPases (Nassar et al., 1998; Li et al., 1997). 
  
1.2.2 The complexity of RhoGAPs for the regulation towards Rho GTPases 
Although RhoGAPs share a common structural mechanism to down-regulate 
Rho GTPases, the regulation process is very complex at the same time. There are more 
than 70 RhoGAPs identified in mammals and 59 to 70 RhoGAP-domain containing 
proteins predicted from human genome (Figure 1.4) (Tcherkezian and Lamarche-Vane, 
2007), much more than the 22 isoforms of Rho GTPases. The excess of RhoGAPs 
indicates that the regulation of Rho GTPases by RhoGAPs is specific and complex. This 
is illustrated by the fact that every Rho GTPase is regulated by multiple GAPs and many 
members of RhoGAPs have GAP activity towards different Rho GTPases. The 
complexity of their regulation is further enhanced by the fact that all GAPs carry multiple 
protein modules, the functions of which remain largely unknown. These protein modules 
include catalytic domains such as protein kinase, Rho GEF and ArfGAP domains, 
protein-protein and protein-lipid adaptor modules such as SH2, SH3, PH and CR domains, 
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BCH domain as well as the conserved RhoGAP domains (Figure 1.4) (Moon and Zheng, 
2003). The varying combination of modules could serve to regulate the dynamic 
disposition, activity as well as an anchorage of molecular assembly in different temporal 
and spatial manners. Thus, aside from being negative regulators of Rho GTPases, 
RhoGAPs play important roles in many aspects of cell dynamics control by integrating 
other signaling pathways with Rho GTPases pathways. 
 
Figure 1.4 Phylogenic tree of the RhoGAP family. 73 RhoGAPs from yeast to human 
were aligned for their RhoGAP domains using the ClustalW program. The focus of this 
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study, human DLC1 protein and its rat homologue p122RhoGAP, are highlighted in a box. 
(Adapted from Tcherkezian and Lamarche-Vane, 2007.) 
 
1.2.3 Cellular functions of RhoGAPs  
1.2.3.1 RhoGAPs in cell migration 
As Rho GTPases are key regulators of cytoskeletal dynamics, some RhoGAPs 
play important roles in cell migration. One mouse RhoGAP, ARAP3, was found to inhibit 
cell spreading and cell migration (Tcherkezian and Lamarche-Vane, 2007). The Cdc42 
specific srGAP participates in a pathway of neuronal cell migration (Wong et al., 2001). 
Recently, our group identified BPGAP1 as a novel RhoGAP that coordinately regulates 
pseudopodia and cell migration via the interplay of its BNIP-2 and Cdc42GAP Homology 
(BCH) domain, RhoGAP domain and proline-rich region. Furthermore, we showed that 
BPGAP1 interacts with a cortical actin binding protein, Cortactin, and facilitates its 
translocation to cell periphery to enhance cell migration (Shang et al., 2003; Lua and Low, 
2004). 
 
1.2.3.2 RhoGAPs in endocytosis and molecule trafficking 
Rho GTPases have emerged as important regulators of endocytosis and 
intracellular molecule trafficking, and RhoGAPs could play a role in such processes 
 14
(Moon and Zheng, 2003). The human RLIP76 interacts with a number of proteins 
involved in endocytosis and it was suggested to play a pivotal role in Ral-mediated 
protein trafficking by integrating Ral and Rho signaling (Awasthi et al., 2003). TCGAP 
has been reported to be involved in insulin-mediated glucose-transport signaling (Chiang 
et al., 2003). Recently, our group showed that BPGAP1 interacts with endocytic protein 
EEN/endophilin II and they together mediate EGFR (epidermal growth factor receptor) 
endocytosis and the activation of ERK signaling (Lua and Low, 2005). 
 
1.2.3.3 RhoGAPs in cell growth, apoptosis and differentiation 
Rho GTPases regulate cell growth and differentiation. RhoGAPs, as the 
regulators of Rho GTPases, are also suggested as regulators of cell growth and 
differentiation. Such activity has been reported for many RhoGAPs. The down-regulation 
on Cdc42 by MgcRacGAP has been implicated in cytokinesis regulation by affecting 
central spindle formation (Zhao and Fang 2005). Mice lacking the RhoGAP p190-B 
display smaller cell size and animal size, a severe reduction in thymus size and brain 
defects. These defects are associated with a failure in cell differentiation possibly as a 
result of upregulated Rho signaling (Sordella et al., 2002). 
Some RhoGAPs may affect cell growth and differentiation through the induction 
of apoptosis. tGAP1 (testicular GAP 1) is a rat protein found in male germ cells, which 
was shown to induce apoptosis of somatic cells. This implicates an important role during 
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spermatogenesis, since a significant number of male germ cells produced from mitosis 
and meiosis are eliminated through apoptosis (Modarressi et al., 2004).  
 
1.2.3.4 RhoGAPs in tumor suppression 
Given the role of Rho GTPases in oncogenesis, the deregulation of RhoGAPs 
could be associated with tumor progression. In fact, many RhoGAPs were suggested as 
candidate tumor suppressors since deletion or downregulation of several RhoGAPs have 
been found in various tumors. For example, deletion, point mutation and insertion of 
GRAF, the focal adhesion kinase associated RhoGAP, were found in patient with 
leukemia (Borkhardt et al., 2000). RhoGAPs Beta-chimaerin and p50RhoGAP are 
downregulated in breast cancer and drug-resistant ovarian cancer cells respectively 
(Kandpal, 2006). Consistently, the expression of some RhoGAPs could suppress 
transformation or metastasis. For example, p190RhoGAP can repress Ras-induced 
transformation in NIH3T3 fibroblast (Wang et al., 1997). Another RhoGAP PI3-kinase 
p85-alpha subunit plays a role in metastasis suppression in ovarian cancer (Kobayashi et 
al., 2004). At same time, some RhoGAPs were found to be upregulated in tumors, such as 
RacGAP1, srGAP1 and p115RhoGAP (Kandpal, 2006). The different effects of various 
RhoGAPs to tumors further implicate that the regulation of Rho GTPases by RhoGAPs is 
a specific and complex process. 
 
 16
1.2.3.5 RhoGAPs in neuronal morphogenesis 
One of the established physiological roles of Rho GTPases is the regulation of 
the actin cytoskeleton during neuronal migration, axonal growth and guidance, and 
formation of synapses. Consequently, RhoGAPs play a role in neuronal morphogenesis. 
In fact, mutations or deletions of various RhoGAP genes have been linked to mental 
defects, such as Myosin-IXa, srGAP3, oligophtrnin-1 (Moon and Zheng, 2003). More 
research has been done to elucidate their function in neuronal morphogenesis. For 
example, α2-chimaerin, a brain specific GAP, was shown to induce neurite outgrowth in 
neuroblastoma cells and to be involved in growthcone collapse (Shi et al., 2007B). 
Another RhoGAP, p190RhoGAP, was shown to be necessary for axon ourgrowth, 
guidance and fasciculation, and neuronal morphogenesis (Brouns et al., 2001). 
 
1.2.3.6 Crosstalks of Rho GTPase pathways and other signaling pathways mediated 
by RhoGAPs 
The multifunctional features of many RhoGAPs make them signal convergent/ 
divergent points to mediate crosstalks between the Rho GTPase signaling and various 
signaling pathways. For example, BPGAP1 activate endocytosis by integrating Rho 
pathway with MAPK pathway (Lua and Low, 2005). RA-RhoGAP integrates Rap1 and 
Rho signaling during neurite ourgrowth (Yamada et al., 2005). The crosstalks mediated 




1.2.4 The regulation on RhoGAPs 
The cellular functions of various RhoGAPs are very specific and different and 
this may attribute to the multiple-domain nature of many RhoGAPs. A RhoGAP protein 
may act as a signal convergent/divergent point by binding various molecules to its 
multiple domains/motifs. Such interactions could serve to regulate the dynamic 
disposition, activity as well as the anchorage of molecular assembly of RhoGAPs in 
different  temporal and spatial  manners.  It  has been found  that  RhoGAPs are regulated 
by various mechanisms, including phosphorylation, phospholipid-binding, protein-protein 
interaction and proteolytic degradation. First, phosphorylation could activate/inhibit the 
activity of many RhoGAPs or even change their specificity towards Rho GTPases (Moon 
and Zheng, 2003). For example, p190 RhoGAP could be phosphorylated on tyrosine 
residues by activated Src or be phosphorylated on serine/threonine by activated protein 
kinase C. The phosphorylation induces conformational change that leads to the 
translocation of p190 and/or activation of its GAP activity (Roof et al., 1998; Hu and 
Settleman, 1997). Another example could be MgcRacGAP, whose GAP specificity is 
changed from Rac1 and Cdc42 to RhoA after serine phosphorylation by ROCK 
(Rho-associated kinase) during cytokinesis (Lee et al., 2004). Second, 
phospholipid-binding were also found to regulate the function of some RhoGAPs. 
Phospholipids interact with non-catalytic motifs of RhoGAPs and could exert regulatory 
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effects on the subcellular localization or catalytic activity of RhoGAPs (Moon and Zheng, 
2003). For example, the interaction of the RhoGAP ARAP3 and phosphatidylinositol 
3,4,5-triphosphate (PIP3) could cause conformational change of ARAP3 to translocate it 
to the plasma membrane and/or to regulate its GAP activity (Krugmann et al., 2004). 
Since phospholipids are important mediators of signal transduction downstream of many 
growth factor receptors, regulation on RhoGAPs by phopholipid-binding could thus link 
RhoGAP function to growth factor stimulation (Bernards and Settleman, 2005). Third, 
protein-protein interaction is one major mechanism that regulates RhoGAP activity. The 
interaction of CdGAP with intersectin and the interaction of TCGAP with Fyn kinase 
present examples for the regulation of GAPs by protein-pretein interactions. Both these 
interactions inhibit the GAP activity of these two RhoGAPs, which is possibly due to 
conformational changes (Jenna et al., 2002). Finally, proteolytic degradation could 
regulate the function of RhoGAPs in a temporal manner by affecting their cellular 
expression levels. It is known that the expression of p190-A RhoGAP is cell cycle 
regulated through ubiquitin-mediated degradation (Su et al., 2003). The various 
regulatory mechanisms together contribute to the efficient and tight control on the GAP 
activity and substrate specificity of so many RhoGAPs (more than 70 in mammals) inside 
the cells. 
 
1.3 DLC1 as a novel RhoGAP protein 
The human gene frequently deleted in liver cancer (DLC1) encoding a novel 
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RhoGAP-domain containing protein was originally identified as a candidate tumor 
suppressor gene (Yuan et al., 1998). It was mapped to chromosome 8p21.3-22. Allelic 
losses from chromosome 8p have been found in various cancers including liver, prostate, 
ovary, breast, lung and colorectal cancers, strongly suggesting the presence of a tumor 
suppressor gene in chromosome 8p (Yuan et al., 1998; Ng et al., 2000 ). Loss of 
heterozygosity of DLC1 was first identified in primary hepetocellular carcinomas (HCCs). 
It was shown that DLC1 gene is deleted in 7 of 16 primary HCCs and in 10 of 11 HCC 
cell lines (Yuan et al., 1998). The chromosomal location of DLC1 gene and its frequent 
downregulation in liver cancer first-time indicated DLC1 protein as a candidate tumor 
suppressor. 
 
1.3.1 Homologues of human DLC1 
There are three homologous proteins sharing the SAM-RhoGAP-START domain 
organization (which will be introduced later) in human, including DLC1, DLC2 and 
DLC3. Human DLC1 amino acid sequence is 58% and 44% identical to human DLC2α 
isoform and human DLC3α isoform respectively (Durkin et al., 2007B). DLC2 and 
DLC3 were also identified as candidate tumor suppressors (Ching et al., 2003; Durkin et 
al., 2007A; Durkin et al., 2007B). It remains to be investigated whether the three human 
homologues cooperate in their cellular functions such as tumor suppression.  
Respective orthologues of the three DLC proteins have been identified in other 
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vertebrate, including mouse, rat, dog, chicken, frog and puffer fish (Durkin et al., 2007B). 
Human DLC1 shares 93% identity and 92% identity in amino acid sequence with the rat 
and mouse orthologues (Durkin et al., 2007B). Its rat orthologue is named as 
p122RhoGAP, which was initially identified as a novel regulator in the phospholipase 
C-delta 1 (PLC-δ1) signaling pathway in screening for PLC-delta 1-binding partners 
from rat brain expression library. It was shown that p122RhoGAP binds to PLC-delta 1 
and activates its activity in hydrolyzing phosphatidylinositol 4,5-bisphosphate (PIP2) 
(Homma and Emori, 1995). It was also shown that p122RhoGAP has a RhoGAP domain 
located near its C-terminus, with GAP activity specific for RhoA, not Rac1. Later 
research found that overexpression of p122RhoGAP inhibits the formation of stress fiber 
and focal adhesions in adherent cells, and leads to cell rounding and detachment. 
However, such effects can be blocked by the constitute-active mutant of RhoA, 
RhoA-G14V. Furthermore, GAP negative mutants of p122RhoGAP, R668E, K706E and 
R710E, lost the function in altering actin cytoskeleton organization (Sekimata et al., 
1999). It was concluded that the cellular morphological changes induced by 
p122RhoGAP are dependent on its GAP activity. Previous work on p122RhoGAP further 
suggested that p122RhoGAP may integrate the downregulation of RhoA and the 
hydrolysis of PIP2 to induce actin cytoskeleton rearrangement. Whether DLC1 is 
similarly involved in PLC signaling has not been addressed yet. Most of the research of 
DLC1 is focused on its RhoGAP function and tumor suppressor function which will be 
introduced in the subsequent sections. 
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1.3.2 Essential function of DLC1 in embryonic development 
DLC1 is widely expressed in all normal adult and fetal tissues in human (Seng et 
al., 2007). Northern blot analysis of mouse DLC1 mRNA shows that mouse DLC1 is also 
widely expressed, with the highest levels in heart, liver and lung (Durkin et al., 2002). 
Using mice as the animal model, homozygous DLC1 inactivation was shown to be lethal. 
The homozygous mutant embryos did not survive beyond 10.5 days post coitum with 
defects in the neural tube, brain, heart and placenta. Cultured fibroblasts from these 
DLC1-deficient embryos have fewer long stress fibers and a reduced number of 
focal-adhesion-like structures (Durkin et al., 2005). These results indicate that DLC1 play 
specific and essential functions in actin cytoskeleton dynamic and embryonic 
development, which can not be compensate by other RhoGAPs or DLC1 homologues.  
 
1.3.3 DLC1 as a tumor suppressor 
Ever since the identification of DLC1 as a candidate tumor suppressor, there have 
been increasing evidence to support this notion. DLC1 was reported to be deleted or 
lowly-expressed in various tumors and cancer cell lines, showing that its downregulation 
contributes to tumorigenesis of such tumors and cancer cell lines. DLC1 gene was initially 
found to be deleted in around 50% of primary HCCs and not expressed in 28% of HCC 
cell lines (Yuan et al., 1998). Similarly, another group also showed that DLC1 was not 
expressed in six of 30 (20%) human HCC samples and 2 of 5 (40%) HCC cell lines, and 
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was deleted in two of six HCC samples and the two HCC cell lines with no DLC1 
expression (Ng et al., 2000). It was further found that DLC1 mRNA was significantly 
underexpressed in the tumor tissue comparing the surrounding nontumorous liver tissue of 
the same patients with HCC (Wong et al., 2003). Besides HCCs, DLC-1 was shown to be 
deleted in 40% of primary breast tumors (Yuan et al., 2003). Low levels or absence of 
DLC1 mRNA were also observed in 57% of primary breast cancer and 62.5% of breast 
cancer cell lines (Plaumann et al., 2003), 70% of breast, 70% of colon, and 50% of 
prostate tumor cell lines (Yuan et al., 2003), 95% of primary non-small cell lung 
carcinoma (NSCLC) and 58% of NSCLC cell lines (Yuan et al., 2004), seven of nine 
human gastric cancer cell lines (Kim et al., 2003), 91% nasopharyngeal carcinoma, 40% 
esophageal, 63% cervical and 33% breast carcinoma cell lines (Seng et al., 2007). 
Recently, microarray technique was used on breast cancers and ovarian cancers, and 
consistently shows similar expression profiles for DLC1 (Goodison et al., 2005; Syed et 
al., 2005). 
Several findings have addressed the issue of how DLC1 is downregulated in 
tumors. In most cases, transcriptional silencing rather than genomic deletion is responsible 
for the downregulation of DLC1 in various tumor samples. It was shown that 
transcriptional silencing of DLC1 is caused by hypermethylation in the promoter region of 
DLC1 gene. Methylation in the DLC-1 promoter CpG island was abserved in HCCs and 
HCC cell lines, non-small cell lung carcinomas, supratentorial primitive neuroectodermal 
tumors, gastric cancer cell lines, nasopharyngeal carcinoma, esophageal, cervical and 
breast carcinomas and Non-Hodgkin's lymphoma (Yuan et al., 2003B; Kim et al., 2003; 
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Wang et al., 2003; Yuan et al., 2004; Pang et al., 2005; Seng et al., 2007; Shi et al., 
2007A). 
Some other work focuses on the suppressive role of DLC1 in tumorigenesis 
mostly using in vitro models. It was shown that DLC1 could inhibit in vitro tumor cell 
growth. When the expression of DLC1 was restored in several cancer cell lines lacking 
endogenous DLC1-expression, their growth was significantly inhibited compared to the 
control cell lines. Such inhibitory effect was shown from less amount of cells proliferated, 
and reduced ability of tumor cells in anchorage-independent growth or in 
colony-formation, in cell lines of HCC, breast cancer, non-small cell lung carcinomas and 
ovarian cancer (Ng et al., 2003; Yuan et al., 2003; Plaumann et al., 2003; Yuan et al., 
2004; Wong et al., 2005; Syed et al., 2005). Furthermore, DLC1 could induce 
caspase-3-mediated apoptosis when restoring its expression in two HCC cell lines and 
three ovarian cancer cell lines. The restoration of DLC1 expression activates caspase-3 
and reduces the level of Bcl-2, an antiapoptotic protein (Zhou et al., 2003; Syed et al., 
2005). The role of DLC1 was further shown in the inhibition of in vitro tumor cell 
migration and invasiveness. These effects have been proved for several HCC cell lines, 
ovarian cancer cell lines and one metastatic breast cancer cell line (Zhou et al., 2004; 
Goodison et al., 2005; Syed et al., 2005; Wong et al., 2005), implicating the role of 
DLC1 as a metastasis suppressor. Recently, in vivo models were used to study the role of 
DLC1 for tumorigenisis under physiological conditions. When introducing DLC1 into 
some cancer cell lines lacking endogenous DLC1 expression, it abolished or significantly 
reduced the ability of these cells to form tumors in athymic nude mice. Consistent results 
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were achieved from several HCC cell lines, breast carcinoma cell lines and NSCLC cell 
lines (Yuan et al., 2003; Zhou X et al., 2004; Yuan et al., 2004; Goodison et al., 2005; 
Wong et al., 2005).  
Taken together, the above findings demonstrate the role of DLC1 as a tumor 
suppressor in tumor growth and metastasis. Meanwhile, the underlying molecular 
mechanism remains unknown. Only recently, progress has been made in elucidating the 
mechanistic functions of DLC1. Their findings will be introduced further in this chapter. 
 
1.3.4 DLC1 as a mutidomain RhoGAP 
Domains are structural units of a protein that can fold independently into 
compact and stable structures (Alberts et al., 2002). Domains are also functional units of 
a protein. They play important roles in regulating many cellular events by their enzymatic 
activities, or by interaction with other moleculars. Some domains possess catalytic 
functions such as phosphorylation activities, protein kinase activities or lipid kinase 
activities. Others can mediate interactions between proteins, or between proteins and 
lipids or nucleic acids (Pawson et al., 2002). The domains mediating interaction can 
target proteins to a specific subcellular location, detect posttranslational modifications or 
molecule-binding on proteins, affect signaling kinetics, nucleate the formation of 
multiprotein signaling complexes, and regulate the conformation, activity, and substrate 
specificity of enzymes (Pawson and Nash, 2003). According to amino acid sequence 
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similarity, domains are divided into various conserved domain families. The same-family 
domains in different proteins not only have consensus amino acid sequences, but usually 
they also have similar tertiary structures and binding properties (Pawson and Nash, 2003). 
The property of a newly identified domain can be predicted from the known structures 
and/or known properties of other domains within the same domain family. Hence, the 
biological functions of a protein can be predicted according to its domain composition 
(Pawson and Nash, 2003). 
Like most RhoGAPs, DLC1 carries multiple protein domains. Two more domains 
as well as the GAP domain were identified in DLC1, when analyzing the amino acid 
sequence of DLC1 (GenBank accession number gi:33188437) with the       
Conserved domain Architecture Retrived Tool (CDART) 
(http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi). One is a Sterile-Alpha Motif (SAM) 
domain flanking the extreme N-terminus of DLC1 followed by a long stretch of sequence. 
The other is a steroidogenic acute regulatory protein (StAR)-related lipid-transfer 
(START) domain flanking the C-terminus of DLC1 (Figure 1.5). For the functions of 
DLC1, functional significance of other regions except the catalytic GAP domain had long 
been unclear. Through studying the conserved properties of the domain families within 
these regions, it may help to predict the molecular mechanism of DLC1 in cell dynamic 
control.  
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Figure 1.5 Schematic diagram showing the composition of protein domains for 
human DLC1. Human DLC1 GenBank accession number gi:33188437. SAM, 
Sterile-Alpha Motif; GAP, GTPase-activating protein; START, StAR-related lipid-transfer 
domains. 
 
1.3.4.1 The RhoGAP domain of DLC1 
The RhoGAP domain of DLC1 possesses in vitro GAP activity specific towards 
RhoA, RhoB, RhoC and Cdc42, but not Rac1 (Wong et al., 2003; Healy et al., 2007). 
Consistently, the in vitro GAP activity of DLC1 rat homolog p122RhoGAP is specific 
towards RhoA, not Rac1, while the activity towards Cdc42 was not examined (Sekimata 
et al., 1999). Since the in vivo activity and in vitro activity of many GAPs are different 
(Moon and Zheng, 2003; Tcherkezian and Lamarche-Vane, 2007), the GAP specificity of 
DLC1 under physiological conditions can not be concluded from the in vitro data. While 
there is no published work showing its in vivo GAP activity towards Cdc42, some data 
indirectly or directly implicate the in vivo RhoA specificity of DLC1. Ectopic expression 
of DLC1/p122RhoGAP could lead to the dissociation of stress fibers (Sekimata et al., 
1999; Wong et al., 2005), showing the downregulating effect on RhoA. The observation 
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that active RhoA could rescue the effects of p122RhoGAP overexpression on actin 
cytoskeleton and cell morphology further demonstrates RhoA as a target of DLC1 in vivo 
(Sekimata et al., 1999). Indeed, DLC1 dramatically reduced RhoA activity at the leading 
edge of cellular protrusions (Healy et al., 2007). 
The GAP activity of DLC1 had long been viewed essential for the anti-tumor 
function. Previous work showed that the RhoGAP activity is essential for the effect of 
DLC1 and p122RhoGAP on cytoskeleton and cell morphology (Sekimata et al., 1999; 
Wong et al., 2005). For both DLC1 and p122, full-length GAP-negative mutants or 
various truncation mutants lacking GAP domain lost the ability in causing the 
dissociation of stress fibers and focal adhesions, cell rounding and detachment (Sekimata 
et al., 1999; Wong et al., 2005). It was further shown that the GAP activity of DLC1 is 
necessary for its tumor suppressor function. The GAP-negative mutant of DLC1 (K714E) 
lost the suppressive effect on colony formation of HCC cells. However, it was also shown 
that the DLC1 GAP domain alone is not sufficient to inhibit the formation of stress fibers 
and the growth of HCC cells, suggesting that the N-terminal region and the C-terminal 
region flanking the RhoGAP domain in DLC1 are also necessary for the tumor 
suppressor function of DLC1, though the exact cellular functions and molecular 
mechanisms of these regions are still unknown (Wong et al., 2005).Subsequently, this 
notion was further supported by the finding that the anti-tumor activity of DLC1 was 
mediated by both RhoGAP-dependant and -independent manners (Healy et al., 2007). 
Previous work together show that GAP function is essential but not enough for the 
function of DLC1, implying that other domains/motifs in DLC1 could play important 
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functional roles which remain to be faithfully elucidated. 
 
1.3.4.2 The SAM domain of DLC1  
SAM domains are found in a wide range of signaling and nuclear proteins. SAM 
domain was originally identified as a novel motif in four proteins essential for the yeast 
sexual differentiation, i.e. byr2, STE11, ste4 and STE50 (Ponting 1995). As such, it is 
named as the sterile alpha motif. Up till now, around 200 SAM-domain-containing 
proteins have been identified in the human genome (Qiao and Bowie, 2005).  
SAM domains from different proteins adopt similar tertiary folds. Each SAM 
domain contains 70-100 amino acids encoding mainly 5 alpha helixes, that fold into a 
conserved globular tertiary structure with a hydrophobic core. 
 Although SAM domains have similar structures, they have versatile binding 
properties and diverse functions. This is shown by the fact that SAM-domain-containing 
proteins exist in all subcellular locations, and they participate in various cellular process 
ranging from signal transduction to transcriptional and translational regulation (Kim and 
Bowie, 2003; Qiao and Bowie, 2005). SAM domains have long been considered as 
protein-protein interaction modules. Many of them can mediate homotypic or heterotypic 
SAM-SAM interactions to form dimmers, oligomers or polymers. For example, the SAM 
domains of several transcriptional repressors, such as TEL (translocation Ets leukemia), 
Polyhomeotic and Sex-comb-on-midleg, can form similar head-to-tail helical homotypic 
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polymer strucutures (Kim and Bowie, 2003). The SAM domains Byr2 and Ste4 mediate 
the formation of oligomers of these two proteins (Kim and Bowie, 2003). Some other 
SAM domains can interact with non-SAM domain containing proteins. For example, 
BAR (Bifunctional Apoptosis Regualtor), a protein involved in apoptotic pathways, can 
bind to Bcl-2 and Bcl-XL via its SAM domain and suppress BAX-induced apoptosis 
through a SAM domain-dependent mechanism (Qiao and Bowie, 2005). Recently, several 
papers reported novel binding properties of some SAM domains, showing that roles of 
SAM domains are not restricted in mediating protein-protein interactions. One surprising 
finding is that the SAM domains of translational repressor Smaug and its homologues 
could bind to stem-loop RNA structures (Green et al., 2003; Aviv et al., 2003). Although 
the function of these SAM domains are completely different from previously studied 
SAM domains, the crystal structure of Smaug-SAM still adopts the conserved globular 
fold and is extremely similar to the SAM domain of EphB2, which has the canonical 
protein binding property. Careful comparison of their structures and sequences shows that 
Smaug SAM has a unique electropositive surface, through which it binds to RNA (Green 
et al., 2003). Such findings may define a novel subfamily of SAM domains with 
nucleic-acid-binding function. Another novel function reported for the SAM family was 
the in vitro lipid-binding property of the SAM domain of p73, a homologue of tumor 
suppressor p53 (Barrera et al., 2003).  
The function of the SAM domain of DLC1 was however barely studied. One 
recent paper suggests that SAM domain is not necessary for the RhoGAP and tumor 
suppressor function of DLC1. It is shown that only SAM domain alone could not cause 
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cell morphological changes or inhibit colony formation, nor could SAM-deletion mutant 
affect these functions of DLC1 to HCC cells (Wang et al., 2005). Meanwhile, 
DLC1-SAM domain could still play a role for the functions of DLC1. Given the fact that 
the regulation of many RhoGAPs is an intricate process inside the cells, DLC1-SAM 
might play its role under physiological conditions. Furthermore, SAM domain could 
participate in other cellular functions of DLC1 in normal cell growth, cell migration and 
embryonic development. 
 
1.3.4.3 The START domain of DLC1 
START domain is defined as a putative lipid-binding module with 200-210 
amino acids. It was first identified as a conserved region at the C-termini of two 
cholesterol-binding proteins, steroidogenic acute regulatory protein (STAR) and 
metastatic lymph node 64 (MLN64). Now 15 START-domain-containing proteins have 
been found in humans (Alpy and Tomasetto, 2005). 
Crystal structures of the START domains of MLN64, STARD4, and 
phophatidylcholine transfer protein (PCTP) have been solved. Their structures share a 
conserved ‘helix-grip’ fold, with α-helixes at the N and C termini and nine β-strands 
forming a β-sheet in the middle. The most striking feature is that, with the C-terminal 
α-helix acting like a lid, the β-sheet forms an internal hydrophobic tunnel, which is big 
enough to accommodate a lipophilic molecule, such as cholesterol and 
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phophatidylcholine (Soccio and Breslow, 2003). With such conserved ‘helix-grip’ fold 
structures, START domains are able to bind lipids. But their target lipids are different. For 
all the known lipid-binding capacity of different START domains, each START domain 
has only one or two specific lipid targets. The identified lipid ligands for 
STARD1/MLN64/STARD5, STARD5, PCTP/STARD10, STARD10 and STARD11 are 
cholesterol, 25-hydroxycholesterol, phosphatidylcholine, phosphatidylethanolamine and 
ceramides respectively (Alpy and Tomasetto, 2005). Their binding specificity may 
indicate that the functions of different START domain-containing proteins are specific 
and not compensable. 
In fact, START domain-containing proteins are involved in various lipid-related 
cellular processes, including lipid trafficking, lipid metabolism, lipid-modulated signal 
transduction and transcriptional regulation. In such processes, the START domain serves 
as a versatile lipid-binding interface that functions as a lipid-transfer and/or lipid-sensing 
domain (Alpy and Tomasetto, 2005). Many START proteins are well known for their 
roles in lipid trafficking and lipid metabolism through their transferring capacity of lipids. 
For example, MLN64 is a transporter of endosomal cholesterol and may play a role in 
cholesterol homeostasis (Alpy and Tomasetto, 2006). STARD10 is concentrated in the 
sperm flagellum and may function in energy metabolism of sperms by transferring 
phophatidycholine PC (Yamanaka et al., 2000). Some other START proteins may regulate 
signal transduction and/or transcriptional machinery by sensing the binding of lipids. For 
example, the START domain of STARD11 was suggested in the regulation of signal 
transduction in the Goodpasture disease by regulating the kinase activity of STARD11 
 32
towards Goodpasture antigen (Raya et al., 2000). The START domain of STARD6 was 
implicated in transcriptional regulation during spermatogenesis through lipid-interaction 
(Gomes et al., 2004). Taken together, START domain-containing proteins make use of the 
lipid-binding capacity to exert different lipid-related cellular functions.  
The function of the START domain of DLC1 remains obscure. 
Multiple-sequence alignment of various START domains shows that DLC1-START has 
the well conserved residues flanking the phosphatidylcholine (PC) binding site of 
PC-transfer protein (Ponting and Aravind, 1999), indicating the potency of DLC1-START 
in binding to lipids like PC. Earlier work on p122RhoGAP revealed that it could interact 
with phospholipase C delta 1 (PLC-δ1) through its C-terminus (including the GAP 
domain and the START domain), suggesting the involvement of p122RhoGAP in 
phospholipase pathway and the potential interaction between its START domain and 
phospholipase or phospholipid(s) (Homma and Emori, 1995; Sekimata et al., 1999). Later 
research showed that the START domain play an auxilliary role in localizing 
p122RhoGAP in caveolin-coated lipid-raft, caveolae, which could be due to the 
lipid-binding capacity of the START domain (Yamaga et al., 2004). But till now there is 
still no direct evidence to show its lipid-binding activity. Recently, one paper showed that 
START-deletion mutant of DLC1 lost the effect in changing cell morphology and the 
inhibition on colony formation of tumors cells by this mutant is less potent than full 
length, demonstrating the functional significance of START domain to the RhoGAP and 
tumor suppressor function of DLC1 (Wong et al., 2005). Despite all these findings, the 
actual role of START domain to the functions of DLC1 remains elusive. 
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1.3.5 Molecular mechanism of DLC1 in cell dynamics  
Recently, several pieces of work started to unravel the possible molecular 
mechanism of DLC1/p122RhoGAP’s functions in cellular signaling. Earlier work showed 
that p122RhoGAP could specifically bind to PLC-δ1 and activate it but not PLC-β1 or 
PLC-γ1, and the C-terminal half of p122RhoGAP is responsible for such interaction 
(Homma and Emori, 1995; Sekimata et al., 1999). One later work shows that 
p122RhoGAP interacts with caveolin and it can localize at caveolin-enriched membrane, 
caveolae, while the functional significance of their interaction is not clear yet (Yamaga et 
al., 2004). Another work identified serine 322 of rat p122RhoGAP (corresponding to serine 
329 in human DLC1) as the phosphorylation site by protein kinase B (PKB) and 
ribosomal S6 kinase (RSK) upon insulin stimulation and it showed the involvement of the 
PI3K/Akt pathway and MEK/ERK/RSK pathway for the phosphorylation, but the 
downstream effect remains elusive (Hers et al., 2006). One recent work suggested that the 
activity of DLC1 RhoGAP domain is essential but not enough for its function and the 
region between 292- to 648-amino acid and the START domain are also necessary for the 
tumor suppressor function of DLC1 (Wong et al., 2005), implicating the importance of 
other domains/regions of DLC1. Most recently, it is clear that DLC1 can interact with the 
tensin family members tensin1, tensin2 and cten, through amino acids 440-445 of DLC1. 
Mutation of tyrosine 442 abolished the focal adhesion localisation of DLC1 targeted by 
tensins and impaired the tumor suppressor function of DLC1 (Yam et al., 2006; Qian et 
al., 2007; Liao et al., 2007). The molecular mechanism of how DLC1 plays its function 
in cell dynamics requires more investigation. It is therefore necessary to study the 
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roles of other regions besides the GAP domain of DLC1 and search for its additional 
interaction partners to further elucidate the mechanistic function of DLC1 in normal cell 
growth, migration, morphogenesis as well as in tumor suppression. 
 
1.4 Hypothesis and objectives of this study 
The fact that GAP domain alone is not sufficient for the function of DLC1 
(Wong et al., 2005) raises the possibility that other regions of DLC1 may interact with 
certain molecules and lead to the crosstalk of RhoA/GAP pathways with other signaling 
arms. It might help us to address this point to identify the binding partner(s) of these 
regions of DLC1 and the interplay of its/their functions with the GAP function of DLC1 
in cell dynamic control. Protein-protein interaction assays and appropriate cell dynamic 
assays would be required to elucidate potential mechanisms underlying the observed 
cellular effects. 
This study may lead to a better understanding on the mechanistic function of 
DLC1 in the complicated signaling network. It may also enhance our understanding on the 
specificity and redundancy of different GAP proteins and different Rho GTPases in cell 
dynamic control. As a tumor suppressor of various kinds of tumors, DLC1 is a potential 
molecule in clinical research for the treatment of cancers. Understanding the mechanism 
of how DLC1 exerts its function in cellular events may contribute to the development of 
cancer-suppressing drugs.  
 35
In summary, we hypothesize that SAM domain, START domain or some 
unidentified motifs in DLC1 could regulate its cellular function in vivo via some 
unidentified interacting partners.  
To test this main hypothesis, the major aims of this thesis work are to: 
z clone human DLC1 cDNA and construct various truncation mutants of DLC1 for 
protein interaction assays and cellular studies; 
z identify potential interacting partner(s) for different regions of DLC1 protein; 
z study the properties of the interactions  by  identifying  their  binding  motifs  
between DLC1 and its interacting partner(s); and 








Materials and methods 
2.1 RT-PCR cloning and plasmid construction  
2.1.1 RNA isolation and RT-PCR 
To acquire the full length cDNA of human DLC1 and human EF1A1, total RNAs 
from human kidney 293T cells were isolated using the RNeasy (Qiagen) according to the 
manufacturer’s instructions. 5 µg of RNA was subjected to the first strand cDNA 
synthesis with Reverse Transcriptase (Roche) using oligo-dT (Operon) as primer for 60 
min at 42oC in a total volume of 20 µl. For PCR reaction, 1 µl of 293T cDNA was 
amplified using specific primers corresponding to the cDNA sequences of NM_006094 
(for human DLC1), NM_178006 (for human DLC2) and NM_001402 (for human EF1A1) 
by the DyNAzyme EXT DNA polymerase (Finnzymes). To facilitate subsequent cloning, 
the PCR primers contain restriction enzyme sites and their sequences were listed at Table 
2.1, 2.2 and 2.3. The following PCR conditions were used: initial denaturation 94 oC for 2 
min; subsequent cycling (35 cycles) at 94 oC for 45 sec, annealing at 55 oC for 30 sec, and 
extension at 72 oC for 3 min 40 sec (for DLC1) or for 2 min (for EF1A1); final extension 
at 72 oC for 10 min. 
Primer name Primer sequence 
DLC1-F 5’ CGGGGATCCATGTGCAGAAAGAAGCCGG 3’  
DLC1-R 5’ CGGCCCGGGTCACCTAGATTTGGTGTCTTTGG 3’  
SAM-R 5' CGGCCCGGGTCAACTTCGTTTCCGATGAGG 3'  
P-F  5’ CGGGGATCCATGCTAGAAATTAGTCCTCATCGG 3’ 
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P-R 5’ CGG CCCGGGTCATGTGCGCTGCACGTTGACCG 3’ 
GAP-F 5’CGGGGATCCCAACCGTTGCCTCAGAGCATCC 3’ 
GAP-R 5’ CGGAAGCTTTCAATGGAAGAGGGAAGGCGC 3’  
R-F 5’ CGGGGATCCATGACCCTGAAGAGAGAG AATTCC 3’  
R-R 5' CGGCCCGGGTCAAGCTGAGTCATCATTACCC 3' 
START-F 5’ CGGGGATCCATGGATGACTCAGCTGACTACC 3’  
P1-R 5’ CGGCCCGGGTCACGCACTGAGGCTCCGGGTCC 3’  
P2-F 5’ CGGGGATCCATGTGCAACAAGCGGGTGGGC 3’  
P2-R 5’ CGGCCCGGGTCACTGATTGACTATCCGCTGC 3’ 
P3-F 5’ CGGGGATCCATGTGGTCGGAGAAGTTTTCTGA 3’  
Table 2.1 Primers used for the cloning of DLC1 full length and domains. Underlined 
are restriction site used for cloning. 
 
Primer name Primer sequence 
DLC2SAM-F 5’ CGGGGATCCATGAAAGAAGCATGTGACTGGCT    3’ 
DLC2SAM-R 5’ CGGCCCGGGTGATTTCATTGAGGCACACTTGT    3’ 
Table 2.2 Primers used for the cloning of DLC2 SAM domain. Underlined are 
restriction site used for cloning. 
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Primer name Primer sequence 
EF1A1-F 5’ GGATCCATGGGAAAGGAAAAGACTC 3’ 
EF1A1-R 5’ CTCGAGTCATTTAGCCTTCTGAGC 3’ 
DOMAIN1-R 5’ CGGCTCGAGTCAACGAGTTGGTGGTAGGATGC 3’ 
DOMAIN2-F 5’ CGGGGATCCATGCCAACTGACAAGCCCTTGC 3’ 
DOMAIN2-R 5’ CGGCTCGAGTCAGTCATTTTTGCTGTCACC 3’ 
DOMAIN3-F 5’ CGGGGATCCATGCCACCAATGGAAGCAGC 3’ 
Table 2.3 Primers used for the cloning of EF1A1 full length and domains. Underlined 
are restriction site used for cloning. 
 
2.1.2 Cloning of the DLC1 and EF1A1 constructs 
The full length PCR products were gel-purified (Qiagen) and cloned into 
Flag-tagged, HA-tagged, GFP-tagged or GST-tagged Pxj40 vector (Dr. E. Manser, 
Institute of Molecular and Cell Biology, Singapore), GST-tagged pGEX-4T-1 vector 
(Pharmacia Biotech) or myc-His-tagged pcDNA3.1 vector (Invitrogen) respectively. The 
resulting bacteria  colonies were screened by double restriction digestion and positive 
clones were sequenced using ABI PRISM Bigdye Terminator Cycle Sequencing kit 
(Applied Biosystem) in both directions to confirm their identity. 
Various cDNA fragments encoding the various domains of DLC1 or EF1A1 or the 
SAM domain of DLC2 were generated from the full-length template using the specific 
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primers in a standard PCR and then gel purified for cloning. The primers used for the 
domain PCR were listed in Table 2.1 and 2.2. (Cloning of BNIP-Sa full length and 
various domain constructs is courtesy of Dr. Zhou Yiting.) 
 
2.1.3 Cloning of deletion mutants and point-mutation mutants of DLC1  
Deletion mutants and point-mutation mutants of DLC1 were generated by 
polymerase chain reaction using specific primers (Table 2.3) with Pfu Turbo DNA 
polymerase (Stratagene). For deletion mutants, the following PCR conditions were used: 
initial denaturation 95 oC for 2 min; subsequent cycling (10 cycles) at 95 oC for 30 sec, 
annealing at 50 oC for 1 min, and extension at 68 oC for 7 min 40 sec; another subsequent 
cycling (15 cycles) at 95 oC for 30 sec, annealing at 50 oC for 1 min, and extension at 64 
oC for 12 min; final extension at 64 oC for 10 min. For point-mutation mutants, the 
following PCR conditions were used: initial denaturation 95 oC for 30 sec; and subsequent 
cycling (16 cycles) at 95 oC for 30 sec, annealing at 55 oC for 1 min, and extension at 68 
oC for 7 min 40 sec. 10 µl of PCR products were digested with 10 unit Dpn I enzyme 
(New England Biolabs) for 2 hour at 37 oC. PCR products for point-mutation mutants 
were subjected to transformation directly. PCR products for deletion mutants were 
subjected to PCR purification (Qiagen), single restriction enzyme digestion, ligation and 
transformation. Several clones from each plate wee selected and sequenced. (Cloning of 
DLC1-SAM-FLF, DLC1-SAM-F38, DLC1-SAM-L39 and DLC1-SAM-F40 is courtesy 
of Dr. Zhang Jingfeng.) 
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Primer Name Primer Sequence 
∆P1-R 5'-CGGGCGGCCGCACTTCGTTTCCGATGAGG-3' 
∆P1-F 5’ CGGGCGGCCGCCTGCAACAAGCGGGTGGGC  3’ 
∆P 3-R 5’ CGGGCGGCCGCCTGATTGACTATCCGCTGC 3’ 
∆P 3-F 5’CGGGCGGCCGCCCAACCGTTGCCTCAGAGC 3’ 
K48AR49A-F 5’GATATTTCCTTGGTCGCGGCAGAGCATGATTTTTTG 
K48AR49A-R 5’ CAAAAAATCATGCTCTGCCGCGACCAAGGAAATATC 3’ 
R64AR65A-F 5’GAGGCTCTATGCGCGGCTCTAAATACTTTA 3’ 
R64AR65A-R 5’ TAAAGTATTTAGAGCCGCGCATAGAGCCTC 3’ 
R677E-F 5’GGATCAGGTTGGGCTCTTCGAAAAATCGGGGGTCAAGTCC 
R677E-R 5’GGACTTGACCCCCGATTTTTCGAAGAGCCCAACCTGATCC
Table 2.3 Primers used for DLC1 deletion mutants and point mutation mutants 
preparation. Underlined are restriction site used for deletion cloning. Mutation sites are 
shown by bold letters. 
 
2.2 Identification of DLC1-interacting partners  
Livers from adult female rats were homogenized in buffer (50 mM HEPES pH 7.4, 
100 mM NaCl, 10 mM MgCl2, 5 mM EDTA, 10% glycerol, 1% Triton X-100, 5 mM 
sodium-orthovanadate, 5 mM glycerol 2-phosphate and a mixture of protease inhibitors) 
using a dounce tissue grinder (Wheaton) with Pestle A and B. The homogenate was 
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centrifugated and the supernatant was carefully collected. Glutathione-sepharose beads 
(Amersham Biosciences) coated with 100 µg GST or GST-SAM were mixed with the 
lysate or just the lysis buffer (as control) and incubated overnight at 4ºC with gentle 
shaking. After extensive washing, the bound proteins were eluted with lysis buffer 
containing 4 M urea, resolved by SDS-PAGE and visualized by sliver staining (Bio-Rad). 
Protein bands excised from SDS-polyacrylamide gels were reduced, alkylated, and then 
in-gel digested with trypsin. Their mass spectra were acquired with a matrix-assisted laser 
desorption ionization-time of flight (MALDI-TOF) mass spectrometer and identified as 
previously described (Lua et al., 2004). 
 
2.3 Cell culture and transfection  
293T cells were grown in RPMI 1640 medium supplemented with 10% (vol/vol) 
fetal bovine serum, 2mM L-glutamine, 100U/ml penicillin, and 100µg/ml streptomycin 
and maintained at 37°C in a 5% CO2 atmosphere, whereas NIH3T3 cells and MCF7 cells 
were grown in DMEM (high glucose) with 10% calf serum or 10% fetal bovine serum 
respectively (all from Hyclone Laboratories, Logan, UT). NIH3T3 were starved for 18-24 
h in medium with 0.5% serum before treatment with 10ng/ml fibroblast growth factor 
(FGF) (Promega) for 20 min. The 293T cells were tranfected using Fugene 6 (Roche 
Diagnostics) according to the manufacturer’s instructions. The NIH3T3 cells and MCF7 
cells were tranfected using PolyMAG Magnetofection reagent (Chemcell) according to 
the manufacturer’s instructions. 
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2.4 Precipitation/pull-down and co-immunoprecipitation studies  
2.4.1 Mammalian cell lysate preparation 
Mamamlian cells were lysed in RIPA buffer containing 150 mM sodium chloride, 
50 mM Tris, pH 7.3, 0.25 mM EDTA, 1% (w/v) sodium deoxycholate, 1% (v/v) Trition 
X-100, 50 mM sodium fluoride, 5 mM sodium orthovanadate and a mixture of protease 
inhibitors (Roche Applied Science). Lysates were directly analyzed, either as whole-cell 
lysates (25 µg) or aliquots (250 µg) used in affinity precipitation/“Pulldown” assays, 
co-immunoprecipitation assays or direct binding studies.  
2.4.2 Preparation of GST-fusion proteins for pull-down experiments 
GST-tagged plasmids in pGEX-4T-1 vector were transfomed into E.coli. DH5α or 
BL21 strains. When bacterial culture growing at 37 oC reached 0.3-0.6 at OD600, 0.1 mM 
IPTG was added in it to induce the expression of GST-tagged proteins with over-night 
shaking at room temperature. The next day, the cell pellets were collected by 
centrifugation at 4 oC, followed by freezing in -80 oC for 1 hour. The pellets were then 
thawed on ice, resuspended in chilled 1XPBS containing 1% Triton-X-100, 1.52% DTT 
(w/v) and a mixture of protease inhibitors (Roche Applied Science) and lysed by 
sonication The cell lysate were centrifuged at 5000 rpm for 1 hour at 4oC. The supernatant 
was incubated with Glutathione Sepharose 4b (Amersham Sciences) at 4oC over night. 
Beads with GST-tagged proteins were washed 3 times with chilled 1XPBS containing 1% 
Triton-X-100 followed by 2-times washing with chilled 1XPBS.  
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2.4.3 Precipitation/pull-down  
Various GST fusion proteins purified on Glutathione Sepharose 4b (Amersham 
Sciences) were incubated with 200 µl mammalian cell lysate at 4oC for 3 hours. The 
beads were then washed 3 times with chilled RIPA buffer. All protein complexes on the 
beads were separated on SDS-PAGE, blotted and probed with indicated antibodies. Blot 
was stripped and stained with amido black to reveal loading of GST-RBD. 
2.4.4 Co-immunoprecipitation 
200 µl mammalian cell lysates expressing Flag-tagged and various epitode-tagged 
proteins were incubated with M2 anti-Flag agarose beads (Sigma-Aldrich) at 4oC for 3 
hours. The beads were then washed 3 times with chilled RIPA buffer. All protein 
complexes were separated on SDS-PAGE, blotted and probed with indicated antibodies. 
2.4.5 G-actin in vitro binding studies  
For G-actin binding studies, 293T cells transfected with Flag-tagged pXJ40 
plasmids were lysed in RIPA buffer as described above. M2 anti-FLAG agarose beads 
(Sigma-Aldrich) were incubated with cell lysis in 4oC for 2 hours and washed 3 times 
with RIPA buffer to purify mammalian expressed Flag-tagged proteins. All Flag-tagged 
proteins purified on beads were incubated with 3µg purified G-actin (Cytoskeleton Inc.) 
in 150 µL 1xPBS with 0.1% Triton X-100 at room temperature for 1.5 hour. Then the 
beads were washed 3 times with 1X PBS with 0.1% Triton X-100. All protein complexes 
were separated on SDS-PAGE, blotted and probed with indicated antibodies. 
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2.5 Direct binding studies 
For in vitro direct binding studies using proteins expressed from mammalian cells, 
293T cells overexpressing His-tagged SAM were lysed in lysis buffer (pH8.0) with 
50mM NaH2PO4, 0.5 M NaCl, 10mM imidazole, 1% Triton-X-100, 5 mM sodium 
orthovanadate and a mixture of protease inhibitors (Roche Applied Science). Ni-NTA 
agarose (QIAGEN) were incubated with cell lysis in 4oC for 2 hours and washed 4 times 
using washing buffer with 50mM NaH2PO4, 0.5 M NaCl and 20mM imidazole (pH6.0). 
His-tagged SAM purified on beads was then eluted by elution buffer with 0.05% 
Tween-20, 250mM imidazole, 300mM NaCl, 50mM NaH2PO4 (pH8.0). Various GST 
fusion proteins immobilized on Glutathione Sepharose 4b (Amersham Sciences) were 
incubated with the eluted His-tagged proteins in 200µl of 1XPBS buffer with 0.1% 
Triton-X-100, 20 mM NaCl and 18 mM imidazole at 4oC for 1 hour, followed by 5-times 
washing with cold 1XPBS containing 0.1% Triton-X-100. All protein complexes were 
separated on SDS-PAGE, blotted and probed with indicated antibody. Blot was stripped 
and stained with amido black to reveal loading of GST-fusion proteins. 
For in vitro direct binding studies using proteins produced from bacteria and TNT 
system, Flag-tagged or HA-tagged proteins were produced in vitro with TNT® T7 Quick 
Coupled transcription/translation system (Promega) according to the manufacturer’s 
instructions. The Flag/HA-tagged proteins were then subjected to pull-down assays with 
GST-fusion proteins purified and immobilized on beads as described above. All protein 
complexes on the beads were separated on SDS-PAGE, blotted and probed with indicated 
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antibodies. Blot was stripped and stained with amido black to reveal loading of 
GST-fusion proteins. 
 
2.6 RBD assay 
The endogenous RhoA activity was examined with pull-down assays with 
GST-tagged RBD domain of rhotekin which can specifically bind to GTP-bound RhoA 
(Ren et al., 1999; Wheeler and Ridley, 2004; Shang et al., 2003). Briefly, cells expressing 
various Flag-tagged proteins were lysed with RIPA buffer. 200 µl of lysates were 
subjected to pull-down assay at 4oC for 30 min with GST-tagged RBD purified on 
glutathione-sepharose beads. Proteins in the whole cell lysate and the protein complex on 
the beads were processed with SDS-PAGE and immunoblotting. Endogenous RhoA, 
over-expressed proteins in the whole cell lysate and the active RhoA pulled down by 
GST-RBD were immunoblotted with indicated antibodies. Blot was stripped and stained 
with amido black to reveal loading of GST-RBD.  
 
2.7 SDS-PAGE gel eletrophoresis and western blot analysis 
The proteins were analyzed on 8% or 15% SDS-polyacrylamide gels (SDS-PAGE) 
with a Mini Protean II electrophoresus apparatus (Bio-Rad Laboratories). The gels were 
cast with 1.5 mm spacers and ten-well combs (Bio-Rad Laboratories). The resolving gel 
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contained 8% or 15% (w/v) acrylamide, 0.48% (w/v) N-N’-methylbisacrylamide, 0.375 
mM Tris-HCl pH 8.8, 0.1% (w/v) SDS, 0.0075% (w/v) AMPS and 0.05% (v/v) TEMED. 
The stacking gels contain 4% (w/v) acrylamide, 0.133% (w/v) N-N’-methylbisacrylamide, 
0.125 mM Tris-HCl pH 6.8, 0.1% (w/v) SDS, 0.0075% (w/v) AMPS and 0.08% (v/v) 
TEMED. Protein samples, together with protein markers (Bio-Rad Laboratories) were 
mixed with 1/5 volumn of 6X loading buffer [3% (w/v) SDS, 15% (v/v) glycerol, 7.5% 
(v/v) b-mercaptoethanol, 0.1 M Tris-HCl pH 6.8, 0.005% (w/v) bromophenol blue] and 
boiled for at 95oC 5 min. Electrophoresis was performed at 50mA/gel for 1 hour at room 
temperature in SDS-running buffer [25 mM Tris, 192 mM glycine and 0.75% (w/v) SDS]. 
After eletrophoresis, proteins separated on the gels were transferred onto PVDF 
membrane (Bio-Rad Laboratories) in transfer buffer [33.7 mM Tris, 256 mM glycine, 
20% (v/v) methanol and 0.01% (w/v) SDS] at 100 Volt for 1.5 hour at 4oC with a Mini 
Trans-Blot Electrophoretic Transfer Cell (Bio-Rad Laboratories).  
The blots were incubated in Blocking buffer (1% BSA, 0.1% Tween 20 in PBS) at 
room temperature for 1 hour and then incubated with primary antibody diluted in 
Blocking buffer at 4oC overnight, followed by 10-min washing using 0.1% Tween 20 in 
PBS at room temperature for 3 times. After that, blots were incubated with secondary 
antibody diluted in PBS with 0.1% Tween 20 for 60 min at room temperature followed by 
10-min washing using 0.1% Tween 20 in PBS at room temperature for 3 times. Proteins 
on the blots were detected with ECL kit (Pierce). Antibodies used were polyclonal rabbit 
anti-HA (Zymed Laboratories Inc.), monoclonal anti-actin and monoclonal M2-anti-Flag 
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(Sigma Aldrich), monoclonal anti-DLC1 (BD Transduction Laboratories, Lexicon, KY), 
monoclonal anti-His (Qiagen), monoclonal anti-EF1A1 (Upstate Biotechnology) and 
polyclonal rabbit anti-GFP (Invitrogen). 
 
2.8 Pyrene Actin polymerization assay  
Pyrene Actin polymerization assays were carried out using Actin polymerization 
Biochem Kit (Cytoskeleton Inc.) according to the manufacturer’s manual. The 
GST-fusion proteins for the test were expressed from 293T cells or E.coli. and purified on 
glutathione beads as described above. Then the beads were incubated with Elution buffer 
(10 mM reduced glutathion in 50 mM Tris-HCl, pH 8.0) at room temperature for 10 min 
to elute the bound GST-fusion proteins. The concentration of the eluted proteins in the 
supernatant was examined by Braford assays (Bio-Rad Laboratories) according to the 
manufacturer’s manual. The quality of the eluted proteins was examined by SDS-PAGE 
gel electrophoresis followed by Commassie-blue staining (0.2% Commassie blue R-250, 
40% methanol, 10% acetic acid). The purified Arp2/3 was purfied from Cytoskeleton Inc. 
50µg monomer pyrene-labeled actin was mixed with 10µg test protein and the mixture 
was incubated at room temperature for 10 minutes. Then 1/10th volume 
actin-polymerization buffer in the mixture was added to initiate actin polymerization. 
Actin polymerization was monitored immediately by pyrene fluorescence (excitation 
365nm, emission 407nm) using Germini spectrofluorometer (Molecular Devices Inc.) 
with time intervals of 30 seconds. 
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2.9 Immnofluorescence 
NIH3T3 cells were seeded on sterilized glass cover slips precoated with 
poly-D-lysine. The next day, cells were transfected with various epitope-tagged 
expression plasmids for DLC1 and/or EF1A1. 4 hours after transfection, cells were 
starved or stimulated as described above. Then the cells on cover slips were fixed in 1X 
PBS cantaining 3% paraformaldehyde at 4oC for 30 min and permeabilized in 1X PBS 
with 0.2% Triton-X-100 at room temperature for 15 min. Then the cells were incubated 
with monoclonal anti-paxillin (BD Transduction Laboratories, Lexicon, KY), polyclonal 
rabbit anti-HA (Zymed Laboratories Inc.) and/or monoclonal M2-anti-Flag (Sigma 
Aldrich) diluted in 1X PBS with 0.1% Triton-X-100 at room temperature for 1 hour 
followed by washing with 1X PBS containing 0.1% Triton-X-100 for 3 times. Next, the 
cells were incubated with Alexa Fluor 594-conjugated donkey anti-rabbit IgG, Alexa 
Fluor 488-conjugated donkey anti-mouse IgG, Pacific Blue-conjugated goat anti-rabbit 
IgG (Molecular Probes, Eugene, OR) and TRITC-phalloidin (Sigma Aldrich) diluted in 
1X PBS with 0.1% Triton-X-100 at room temperature for 1 hour followed by washing 
with 1X PBS containing 0.1% Triton-X-100 for 5 times. Cells on the cover slips were 
examined under a fluorescence microscope or a confocal fluorescence microscope 
(Olympus FV500). All images were captured with a ×100 objective lens or a 




2.10 Cell migration assay  
Migration assays were carried out with a modified Boyden chamber (24-well 
Transwell, Corning Costar; 8 µm pore size) as previously described (Shang et al., 2003). The 
lower surface of the filter was coated with 5 µg/ml fibronectin (Sigma) as a chemoattractant 
at 37oC for 1-2 hours. Transfected NIH3T3 or MCF7 cells were seeded in the Boyden 
chamber at a density of 1.5X105 in 100 µl of DMEM (high glucose) with 0.2% bovine serum 
albumin. The lower compartment was added with 600 µl DMEM (high glucose) containing 
10% serum. Equal amount of cells were seeded in 6-well plates in DMEM with 10% serum 
to show the relative total amount of transfected cells. Cells were allowed to migrate for 4 h or 
12 h as described in the results. Then the cells that did not penetrate the filters were 
completely wiped off with cotton swabs. The cells transfected with green fluorescence that 
has migrated to the lower surface and the total transfected cells in the 6-well plate were fixed 
with 1X PBS with 4% paraformaldehyde and counted in different fields under a fluorescence 
microscope. In certain experiments, GFP plasmid was used as marker because the 
fluorescence of GFP-tagged DLC1 is much fainter than the GFP control. In another set of 
migration assays, NIH3T3 cells were transiently transfected with cell marker pCMV-βGAL 
alone (Ctrl) or together with 4 times quantity of epitode-tagged plasmids. Cells expressing 
pCMV-βGAL were shown by their blue color after fixation with 1X PBS with 4% 
paraformaldehyde and over-night incubation with X-GAL buffer (1X PBS containing 4 mM 
potassium ferricyanide, 4 mM potassium ferrocyanide, 2 mM MgCl2 and 1 mg/mL X-GAL) 








3.1 Cloning of DLC1 
Full length cDNA for DLC1 was generated by reverse-transcription based 
polymerase chain reaction from total RNA isolated from human 293T (Figure 3.1) and 
verified by sequencing entirely in both directions. For further binding and functional 
studies, full length and different truncation mutants of DLC1 were made as epitope-
tagged recombinants by suitable primers designed (see Materials and Methods) that 
would express fragments of DLC1 protein (Figure 3.2).  






Figure 3.1 Molecular cloning of human DLC1 cDNA. RT-PCR was performed to 
















Figure 3.2 Schematic diagram showing the composition of protein domains of 
different truncation mutants of DLC1 protein.  
 
3.2 Identifying EF1A1 as a novel interacting partner of DLC1-SAM domain 
The GAP domain of DLC1 was known to be important for the effects of DLC1 in 
changing cell morphology and suppressing tumorigenesis (Wong et.al., 2005). We 
hypothesized that other regions on DLC1 might modulate the function of DLC1 through 
the interplay with its GAP activity. Since a variety of SAM domains are widely used as 
regulatory modules in various cell activities through different mechanisms (see Chapter 
1), the SAM domain of DLC1 (henceforth called DLC1-SAM) might as well has a 
regulatory function to the full length DLC1 protein. Therefore, we first sought to find out 
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whether the SAM domain might play a role in modulating the function of DLC1. 
 
3.2.1 Multiple sequence alignment of various SAM domains  
We hypothesized that the function of DLC1 might be regulated by the interaction 
of DLC1-SAM with some unknown molecule(s). However, it is uncertain whether such 
molecule(s) are proteins, nucleotides or lipids, since various binding properties have been 
found for different SAM domains, including protein-binding, DNA/RNA-binding and 
even lipid-binding property (Qiao and Bowie, 2005). In order to predict the putative 
binding property and putative binding partner(s) of DLC1-SAM, multiple sequence 
alignment of DLC1-SAM and several SAM domains with known structures and/or 
various known binding properties was carried out using the program CLUSTALW 
(http://www.ebi.ac.uk/clustalw) (Figure 3.3A). The alignment result shows that the amino 
acid sequence of DLC1-SAM is highly similar to DLC2-SAM and their sequences share 
73% identity. However, the binding property and function of DLC2-SAM is also 
unknown yet. Except for DLC2-SAM, DLC1-SAM shares low degree of identity (<20%) 
with other SAM domain sequences, indicating the binding partner of DLC1-SAM could 
be different from other SAM domains. Here, the phylogenetic tree generated by the 
alignment shows that DLC1-SAM is more closely related to the SAM domains of BAR, 
FLI1, EphA4 and EphB2 and less close to the SAM domains of p73-SAM, VTS1-SAM 
and Smaug-SAM (Figure 3.3B). The SAM domains of BAR, FLI1, EphA4 and EphB2 
are involved in protein-protein interaction, whereas p73-SAM has potential lipid-
binding property, and VTS1-SAM and Smaug-SAM have nucleotide-binding 
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property (Qiao & Bowie, 2005; Green et al., 2003; Aviv et al., 2003; Stapleton et al., 
1999; Smalla et al., 1999; Mackereth et al., 2004). The alignment result shows that 




















Figure 3.3 Homology of DLC1-SAM with other SAM domains of known 
structures/binding properties. (A) Multiple sequence alignment was generated using 
the program CLUSTALW (http://www.ebi.ac.uk/clustalw) with default settings. Residues 
totally conserved in all sequences are shaded black, those conserved in most of the 
sequences are in dark grey, while the significant but least conserved ones are in light grey. 
Species abbreviations: hs, Homo sapiens, mm, Mus musculus; sc, Saccharomyces 
cerevisiae. GenBank accession number gi: hsDLC1, 33188437; hsDLC2, 28976169; 
mmEPHA4, 30705030; hsEPHB2, 119615430; hsFLI1, 14603316; scSTE11, 609414; 
mmBAR, 21313130; scVTS1, 74583753; hsARAP2, 16118245; mmSAMSN1, 10800126. 
(B) Phylogenetic tree generated by the alignment shows the evolutionary relationship for 
the SAM domains of various proteins. 
 
3.2.2 DLC1-SAM does not mediate homophilic interaction 
Based on the alignment result that DLC1-SAM is more closely related to the 
SAM domains with canonical protein-binding property, we set out to investigate the 
protein-binding activity of DLC1-SAM. Since many SAM domains can lead to 
homophilic  interaction to form dimers, trimers or even oligomers  (Qiao & Bowie, 
2005), we wondered whether DLC1-SAM can bind to itself. To investigate whether 
DLC1-SAM has homophilic binding property, protein-precipitation was carried out using 
bacterial-expressed GST-tagged SAM and the lysate of human 293T embryonic kidney 
epithelial cells expressing Flag-tagged SAM (Figure 3.4A). 293T cells were used because 
293T cell line is good for protein expression. The result shows that GST-SAM could not 
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pull down Flag-tagged SAM from whole cell lysate. To further confirm that DLC1-SAM 
could not mediate homophilic interaction, immunoprecipitation assay was carried out 
using Flag-tagged SAM co-expressed with HA-tagged DLC1 full length in 293T cells 
(Figure 3.4B). The immunoprecipitation result shows that DLC1-SAM could not mediate 
interation with DLC1 full length either. Our conclusion was further supported by our 
collaborators’ results showing that DLC1-SAM exists in a monomeric form even at a 
protein concentration of ~1 mM as demonstrated from dynamic light scattering, gel 
filtration and NMR relaxation experiments (courtesy of Dr. Yang Daiwen, Yang Shuai 
and Dr. Zhang Jingfeng). 
A                                                    B 
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Figure 3.4 The SAM domain of DLC1 does not mediate homophilic interaction. (A) 
GST- SAM purified on glutathione-sepharose beads were used for pull-down (PD) assay 
with 293T whole cell lysates (WCL) expressing Flag-tagged SAM. (B) Whole cell lysates 
of 293T cells transfected with Flag-tagged SAM and HA-tagged DLC1 were incubated 
with M2-anti-Flag beads and Flag-constructs were immunoprecipitated (IP) on the beads. 
(A, B) The associated proteins were then separated on SDS-PAGE, blotted and probed 
with indicated antibodies. Blot in (A) was stripped and stained with amido black to reveal 
loading of GST recombinants (bottom panel). 
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3.2.3 EF1A1 is a novel DLC1-interacting partner 
Although DLC1-SAM can not bind to itself, it might interact with other proteins. 
So we continued to identify its putative protein target(s) by using protein precipitations 
and MALDI-TOF mass spectrometry analyses. Purified GST and GST-tagged DLC1-
SAM on glutathione beads were incubated with the rat liver homogenates or lysis buffer. 
One unique band of 48 kDa was consistently observed (Figure 3.5A; arrow). Further 
tryptic digests and analyses by matrix-assisted laser desorption/ionization-time of flight 
(MALDI-TOF) mass spectrometry revealed various peptides that formed different parts 
of eukaryotic translation Elongation Factor 1 alpha 1 (EF1A1, previously known as EF-
1α) (with 23% coverage of total sequence; Figure 3.5B), showing EF1A1 as the putative 














































        1 MGKEKTHINI VVIGHVDSGK STTTGHLIYK CGGIDKRTIE KFEKEAAEMG KGSFKYAWVL 
       61 DKLKAERERG ITIDISLWKF ETSKYYVTII DAPGHRDFIK NMITGTSQAD CAVLIVAAGV 
      121 GEFEAGISKN GQTREHALLA YTLGVKQLIV GVNKMDSTEP PYSQKRYEEI VKEVSTYIKK 
      181 IGYNPDTVAF VPISGWNGDN MLEPSANMPW FKGWKVTRKD GSASGTTLLE ALDCILPPTR 
      241 PTDKPLRLPL QDVYKIGGIG TVPVGRVETG VLKPGMVVTF APVNVTTEVK SVEMHHEALS 
      301 EALPGDNVGF NVKNVSVKDV RRGNVAGDSK NDPPMEAAGF TAQVIILNHP GQISAGYAPV 
      361 LDCHTAHIAC KFAELKEKID RRSGKKLEDG PKFLKSGDAA IVDMVPGKPM CVESFSDYPP 




 Figure 3.5 Identification of Elongation Factor 1A1 as a novel partner of DLC1. (A) 
GST-SAM expressed and purified from E. coli was immobilized on glutathione-
sepharose beads and incubated either with lysis buffer (B) or rat liver lysate (L). As 
controls, GST beads were mixed with the lysate or the GST-SAM incubated with the lysis 
buffer and processed the same way. After elution, bound proteins were resolved by SDS-
PAGE and visualized by silver staining. A unique band around 48 kDa bound to the SAM 
domain of DLC1 (lane 3, labelled by arrow). (B) The band was subjected to trypsin-
digestion followed by MALDI-TOF analysis (see Methods) and identified as elongation 




 EF1A1 is very abundant in cells. To confirm that EF1A1 was indeed a bona fide 
partner of DLC1 in vivo and in vitro, coimmunoprecipitation and GST-pulldown 
experiments were conducted. First, the interaction between full-length DLC1 and EF1A1 
was examined. 293T cells were transfected with Flag-tagged DLC1 full length. Whole 
cell lysate of untransfected cells was used as negative control. Figure 3.6A shows that 
endogenous EF1A1 could be co-immunoprecipitated with Flag-tagged DLC1 but not in 
the untransfected negative control, confirming their existence as a physiological complex 
in vivo. Next, 293T cells were transfected with Flag-tagged EF1A1 and were kept under 
quiescent state (Q) in medium without serum or were stimulated (S) with 10% serum 
after starvation before collection for IP. Consistently, immunoprecipitation of Flag-tagged 
EF1A1 also detected the endogenous DLC1 where their interaction appeared to increase 
moderately by treatment with serum (Figure 3.6B).
  
Second, the interaction between DLC1-SAM and EF1A1 was examined. Since the 
amino acid sequences of DLC1-SAM and DLC2-SAM are very similar with 73% identity 
(Figure 3.3A), we wondered whether EF1A1 has affinity only towards DLC1-SAM or 
towards both DLC1- and DLC2-SAM. Pulldown experiments were carried out using GST, 
GST-tagged DLC1-SAM or DLC2-SAM expressed in E.coli. and purified on glutathione 
beads with whole cell lysate of 293T cells. Figure 3.6C shows pulldown using GST-
DLC1-SAM readily detected endogenous EF1A1, but neither the GST control nor the 
GST-DLC2-SAM could pull down EF1A1, showing the interaction specificity of DLC1-SAM 
and EF1A1. It is not clear why the amount of EF1A1 pulled down by GST-DLC1-SAM 
 60
is so little compared to the amount of EF1A1 in the lysate. This may be explained by the 
fact that a large portion of EF1A1 already forms complexes of the protein synthesis 
machinery or interacts with other binding partners inside the cells. Thus only a small 
portion of EF1A1 from the cell is free to bind to GST-DLC1-SAM. An alternative 
explanation would be that the binding between EF1A1 and SAM might be transient, i.e. 
the complex formed by EF1A1 and SAM may associate and disassociate quickly. 
Therefore only a part of EF1A1 that has ever bound to GST-DLC1-SAM can be shown 
by the pull-down result. It is also possible that the binding buffer may not have the 
optimum ionic condition for their binding and it may affect their binding affinity. 
Next, coimmunoprecipitation assays were carried out using 293T cells 
overexpressing GFP-tagged EF1A1 together with Flag-tagged DLC1-SAM or a Flag-
tagged control protein. Here, EF1A1 was fused with GFP tag to raise its molecular 
weight to avoid overlapping in the SDS-PAGE with the heavy chains of the M2-anti Flag 
antibody from the immunoprecipitation. Likewise, Figure 3.6D shows that 
immunoprecipitation of Flag-tagged SAM domain but not the unrelated protein control, 
detected GFP-tagged EF1A1. Altogether, our results confirm that EF1A1 is a novel bona 




































































Figure 3.6 EF1A1 binds to full length DLC1 and DLC1-SAM in vitro and in vivo. (A) 
Whole cell lysates (WCL) of untranfected 293T cells or cells transfected with Flag-
tagged DLC1 were incubated with M2-anti-Flag beads and Flag-constructs were 
immunoprecipitated (IP) on the beads. Bound proteins were separated on SDS-PAGE, 
blotted and probed with indicated antibodies to reveal the bound endogenous EF1A1. 
Asterisk indicates heavy chains of the anti-Flag antibody on the M2-beads. (B) IP, SDS-
PAGE and immuno-blotting as in (A) were used with cell lysate expressing Flag-tagged 
EF1A1 to reveal the bound endogenous DLC1. Cells were kept under quiescent state (Q) 
or were stimulated (S) with 10% serum after starvation before collection for IP. (C) GST, 
GST-DLC1-SAM or GST-DLC2-SAM purified on glutathione-sepharose beads were 
incubated with 293T cell lysates. The associated proteins were separated on SDS-PAGE, 










Flag-constructs:    SAM     SAM Ctrl     Ctrl SAM   SAM Ctrl     Ctrl
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with amido black to reveal loading of GST recombinants (bottom panel). (D) 293T cells 
co-expressing GFP-EF1A1 with either Flag-tagged SAM or an unrelated control (Ctrl) 
were made quiescent or stimulated with 10% serum after starvation and lysates 
immunoprecipitated with M2-anti Flag beads. Bound proteins on the beads were 
processed to reveal Flag-tagged constructs and the bound GFP-EF1A1.  
 
However, SAM and EF1A1 did not interact with one another when both of them 
were produced as bacterial fusion proteins as shown from dynamic light scattering and 
gel filtration experiments by our collaborator (courtesy of Dr. Yang Daiwen, Yang Shuai 
and Dr. Zhang Jingfeng), suggesting that their interaction could either involve additional 
modifications or extra partner(s). To examine this, direct binding studies were carried out. 
His-tagged SAM was overexpressed and purified from human 293T cells instead of the 
bacterial host, through which DLC1-SAM was produced with post-translational 
modification and suitable folding in eukaryote cells, and at the same time in a more pure 
state for the binding assay. Then the purified His-SAM was subjected to protein pulldown 
assay (Figure 3.7A). His-SAM was strongly enriched by GST-EF1A1 and not by the GST 
control. Interestingly, there are two close bands at 15 kDa in the purified His-tagged 
SAM sample and only the upper band was enriched by GST-EF1A1. We wondered 
whether these two bands were really DLC1-SAM or just non-specific proteins from 293T 
cells. To confirm the identity of the two bands, purified His-SAM sample prepared as 
above was analyzed on SDS-PAGE and stained by PAGE-BLUE (Figure 3.7B). These 
two bands were then cut out separately and sent for analyses by MALDI-TOF mass 
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spectrometry after tryptic digests. MALDI-TOF results confirmed that both of the two 
bands are His-tagged DLC1-SAM. However, due to the low amount of proteins and 
their small molecular weight, the differences of the SAM in the two bands could not be 
identified from the MALDI-TOF results. Possible explanation for the result that purified 
His-SAM from 293T cells existed as two bands in the SDS-PAGE and only the upper 
band could bind to EF1A1, could be that additional post-translational modification(s) or 
different folding of the SAM domain in eukaryotic system for the upper band is necessary 
for the binding between DLC1 and EF1A1. To further substantiate their direct interaction, 
Flag-tagged DLC1 was transcribed and translated in vitro and then subjected to pulldown 
assays by GST-EF1A1. Rabbit reticulocyte in vitro translation system was used here to 
express Flag-tagged DLC1 because proteins produced in this system is more pure than 
proteins expressed from mammalian cells while proteins could have proper folding and 
posttranslational modifications from eukaryote translation system (Glass and Pollard, 
1990).  The result consistently shows that Flag-tagged DLC1 interacted with GST-EF1A1 
but not the GST control (Figure 3.7C). Altogether, these results show that the interaction 


















































































Figure 3.7 EF1A1 directly binds to full length DLC1 and DLC1-SAM. (A) GST or 
GST-EF1A1 purified on glutathione-sepharose beads were incubated with or without His-
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tagged SAM overexpressed and purified from 293T cells (see Materials and Methods). 
GST proteins and the bound His-SAM were separated on SDS-PAGE, blotted and probed 
with anti-Histidine antibodies (upper panel). Blot was stripped and stained with amido 
black to reveal loading of GST recombinants (bottom panel). (B) His-SAM expressed 
and purified from 293T cells was analyzed on SDS-PAGE and the protein gel was stained 
by PAGE-BLUE. Bands in the four wells at the same size were then cut out and sent for 
analyses by MALDI-TOF mass spectrometry after tryptic digests. (C) Flag-tagged DLC1 
was transcribed and translated in vitro and incubated with either GST or GST-EF1A1 
beads. GST proteins and the bound Flag-DLC1 were separated on SDS-PAGE, blotted 
and probed with Flag antibodies (upper panel). Blot was stripped and stained with amido 
black to reveal loading of GST recombinants (bottom panel). PD: pull down. 
 
3.2.4 Two distinct motifs of EF1A1 are involved in binding to DLC1-SAM 
EF1A1 comprises 3 distinct structural domains: Domain I at the N-terminus, the 
middle Domain II and Domain III at the C-terminus (Figure 3.8A). Domain I consists of 
a GDP/GTP-binding domain which binds to GTP in the active state of EF1A1, while 
Domains II and III are involved in the binding to aminoacyl-tRNA. Domains I and III 
have also been shown to be involved in binding globular-actin (G-actin) and bundling 
filamentous-actin (F-actin) (Murray et al., 1996; Liu et al., 2002; Gross et al., 2005). We 
next set out to examine which part(s) of EF1A1 was involved in mediating its interaction 
with the DLC1-SAM domain so as to explore their binding mechanism. First, pulldown 
using GST-fusion of these three domains was carried out with His-SAM purified from 
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293T cells to detect the binding affinity of SAM to the three domains. The pulldown 
result shows that Domain III interacted most strongly with SAM. Binding to Domain I 
and Domain II was very weak or negligible under this condition (Figure 3.8A). To 
investigate whether their in vivo binding affinity was similar, immunoprecipitation assays 
were carried out using the HA-tagged full-length EF1A1 or its 3 domains co-expressed 
with either Flag-tagged DLC1 full-length or Flag-tagged SAM in 293T cells. 
Interestingly, both of the results show that binding by HA-Domain I alone is stronger than 
full length. By comparison, full-length EF1A1 or its Domain III interacted with either the 
full-length DLC1 or its SAM domain with similar  affinity (Figure 3.8B & 3.8C). These 
results support the notion that binding of DLC1-SAM with EF1A1 are likely to be 
complex and could involve certain modulation on either one or both proteins in vivo. 
Taken together, these results confirm the specific interaction between the SAM domain of 
DLC1 and EF1A1 in vitro and in vivo. The molecular basis and the cellular and 
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Figure 3.8 DLC1-SAM binds to distinct domains of EF1A1 in vitro and in vivo. (A) 
GST fusion of domain I (DI), domain II (DII)., and domain III (DIII) of EF1A1 were 
constructed based on the structure previously determined and indicated by the schematic 
diagram (upper panel). They were expressed in E. coli and purified on glutathione-
sepharose beads. They were incubated with purified His-tagged SAM expressed in 293T 
cells and bound proteins were processed as described in Figure 2E. As negative controls, 
beads were incubated with buffer without His-SAM. (B, C) Whole cell lysates (WCL) 
from cells co-expressing HA-tagged EF1A1 full length (FL)., DI, DII or DIII  and Flag-
tagged DLC1 full length (B), or SAM (C) were used for immunoprecipitation (IP) with 
M2-anti Flag beads. WCL and IP samples were immunoblotted with indicated antibodies. 




3.2.5 Identifying key EF1A1-binding motif in DLC1-SAM  
3.2.5.1 Prediction of putative EF1A1-binding motif in DLC1-SAM  
Given the pleotropic roles of various members of the SAM superfamily (Qiao and 
Bowie, 2005), it is important to examine the structure-function relationship of DLC1-
SAM and how it interacts with EF1A1. So we continued to identify key EF1A1-binding 
motif in DLC1-SAM domain.  
The NMR solution structure of DLC1-SAM (PDB ID: 2GYT) had been solved by 
our collaborator. The structure of DLC1-SAM shows that the SAM domain of DLC1 
consists of four α-helices connected by well-defined loops (courtesy of Dr. Yang Daiwen, 
Yang Shuai and Dr. Zhang Jingfeng), which is different from the five-α-helice structure 
of most SAM domains (Qiao and Bowie, 2005). Based on the structure of DLC1-SAM, 
we tried to predict putative key EF1A1-binding residues. Protein-protein association can 
result from both hydrophobic and electrostatic/hydrogen bonding interactions between 
interfaces that comprise complementary nonpolar and charged/polar residues. A common 
type of interactive surface contains a hydrophobic patch surrounded by polar groups 
(Larsen et al., 1998). There are three such regions on the DLC1-SAM surface (shown by 
circle in Figure 3.9B). In order to map out the binding site(s) of DLC1-SAM to EF1A1, 
we designed several SAM mutants with mutated residues in or close to the three potential 
binding interfaces and also some charged residues that could mediate binding by 
electrostatic interaction (shown by dotted circle in Figure 3.9B). They are: one double-
mutant, K48A/R49A, one triple-mutant, F38G/L39G/F40G, and two quartet-mutants, 
K48A/R49A/R64A/R65A and F28G/F53G/L54G/A58G. The mutations were chosen on 
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the basis of the structure and van der Waals surface so that the mutants can retain the 3D 
structure of the wild type protein. Except for A58, all mutated hydrophobic residues were 
located in loop regions or the end of regular secondary structure elements. These mutants 





Figure 3.9 Putative EF1A1-binding motifs in DLC1-SAM. (A) Ribbon drawing of the 
10 lowest-energy conformers of the solution structure of DLC1-SAM. The four helices 
are indicated in red/yellow. (B) Views of the van der Waals surface of DLC1-SAM, 
illustrating potential EF1A1-binding interfaces. The side chains are colored as green = 
hydrophobic, blue = basic, red = acidic and gray = polar (and main chain). Potential 
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EF1A1-binding hydrophobic patch surrounded by polar groups are shown by circle. 
Potential EF1A1-binding charged residues are shown by dotted circle. (The solution 
structure and the van der Waals surface courtesy of Dr. Yang Daiwen, Yang Shuai and Dr. 
Zhang Jingfeng.) 
 
3.2.5.2 Residues F38 and L39 constitute key EF1A1-binding motif on DLC1-SAM 
Next, we used mutants designed above for the immunoprecipitation assays to 
examine whether such mutations could decrease the binding affinity between DLC1-
SAM and EF1A1. Flag-tagged wild type SAM, its mutants or an unrelated Flag-tagged 
control were co-expressed with HA-tagged EF1A1 in 293T cells and 
coimmunoprecipitations were carried out. The double-mutant K48A/R49A and the 
quartet-mutant K48A/R49A/R64A/R65A retained the binding to EF1A1 (Figure 3.10A), 
suggesting that the positively charged residues alone are not responsible for the binding. 
By comparison, the quartet-mutant F28G/F53G/L54G/A58G also retained the binding, 
yet the triple mutant F38G/L39G/F40G (abbreviated as FLF mutant hereafter) had 
significantly reduced binding. In order to confirm that the loss of binding between SAM-
FLF and EF1A1 is not the result of spoiled secondary structure, CD spectra was carried 
out by our collaborator. CD spectra showed that this triple-mutant maintained the 
structure of the wild type (Figure 3.10B) (courtesy of Dr. Yang Daiwen, Yang Shuai and 
Dr. Zhang Jingfeng). Therefore, DLC1-SAM interacts with EF1A1 via either one or both 
of the two hydrophobic regions which are centered by or close to F40.  
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It is worth noting that the homologous DLC2-SAM did not show binding activity 
with EF1A1 (Figure 3.6C), though its structure is very similar to DLC1-SAM due to their 
high similarity on amini acid sequence (Li et al., 2007; Kwan and Donalson, 2007). 
Although both of DLC1 and DLC2 SAM domains contain four α-helices, there are a 
number of significant differences, including their hydrophobic surfaces. Our result shows 
that triple mutation on residues F38G, L39G and F40G on DLC1-SAM had significantly 
reduced its binding to EF1A1 (Figure 3.10A). We wondered whether these residues could 
attribute to the EF1A1-binding selectivity towards DLC1-/DLC2-SAM (Figure 3.6C). So 
we first examined whether F38G, L39G and F40G of DLC1-SAM are conserved in 
DLC2-SAM. The alignment of their SAM domain sequences shows that F40 is conserved 
while F38 and L39 are substituted to S82 and Q83 in DLC2-SAM (Figure 3.10C). 
Further comparison of their structures shows that  DLC2-SAM lacks the hydrophobic 
surface containing F38 and L39 in DLC1-SAM due to these residues being substituted to 
S82 and Q83 respectively (Figure 3.10D) (structure comparison courtesy of Dr. Yang 
Daiwen, Yang Shuai and Dr. Zhang Jingfeng).  It is possible that it is F38 and/or L39 but 
not F40 that contribute to the binding selectivity of EF1A1. To examine this, we further 
designed mutants with single-point mutation at the three FLF residues, F38G, L39G and 
F40G, and carried out immunoprecipitation assays.  293T cells were used to coexpress 
HA-tagged EF1A1 with Flag-tagged DLC1 wild type SAM, FLF triple mutant, the three 
single-point mutants or DLC2-SAM. Figure 3.10E shows that single-point mutations 
F38G and L39G reduced the binding to EF1A1 as significantly as triple mutant FLF, yet 
the F40G mutant still retained the full binding ability to EF1A1. Consistent with the 
previous pulldown assay result (Figure 3.6C), DLC2-SAM did not bind to EF1A1 in the 
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coimmunoprecipitation assay (Figure 3.10E). These results suggest that the hydrophobic 
region containing F38 and L39 constitute a key binding motif that mediates the 
interaction between DLC1-SAM and EF1A1 and it contributes to the binding selectivity 
of EF1A1 towards DLC1-/DLC2-SAM. 
Taken together, through structural and binding studies, we had identified residues 
F38 and L39 residues constitutes key EF1A1-binding motif on DLC1-SAM domain. This 
finding is important as comparing the cellular effects of EF1A1 with the wildtype and the 
non-interactive FLF mutant of DLC1 will allow immediate assessment of the functional 
consequence of their interactions. 
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Figure 3.10 Identifying EF1A1-binding motif in DLC1-SAM. (A) 293T cells were co-
transfected with plasmids encoding HA-EF1A1 and Flag-tagged SAM wild-type (WT), 
one double mutant, K48A/R49A, one triple mutant, F38G/L39G/F40G, or two quartet 
mutants, K48A/R49A/R64A/R65A, F28G/F53G/L54G/A58G or a Flag-tagged control 
encoding an unrelated protein (Ctrl). Whole cell lysates (WCL) were used for 
immunoprecipitation (IP) and incubated with M2-anti-Flag beads. WCL and IP samples 
were immunoblotted with indicated antibodies. Asterisk indicates the light chain of Flag 
antibodies. (B) CD spectra of the wild type and FLF mutant. The unit of mean residue 
ellipticity is deg · cm2 · dmol-1 · residue-1. The protein concentration was 20 µM. The 
spectra were acquired in 0.1-cm-pathlength cells. The conditions were 50 mM sodium 
phosphate, pH 7 at 25 °C. (C) Sequence alignment of DLC1-SAM (residues 11-76) and 
DLC2-SAM (residues 55-119) was generated as described in Fig. 3.3A. Residues totally 
conserved in all sequences are shaded black, those conserved in most of the sequences 
are in dark grey, while the significant but least conserved ones are in light grey. Asterisks 
indicate the corresponding residues of F38, L39 and F40 in DLC1-SAM. (D) Views of 
the van der Waals surface showing four hydrophobic residues A16, Y35, F38 and L39 on 
the EF1A1-binding motif of DLC1-SAM and four corresponding residues of DLC2-SAM 
(i.e. A21, Y40, S43 and Q44). (E) 293T cells were co-transfected with plasmids encoding 
HA-EF1A1 and Flag-tagged DLC1-SAM wild-type, one triple mutant, F38G/L39G/F40G, 
three single-point mutants, F38G, L39G, F40G or DLC2-SAM. Whole cell lysates were 
used for immunoprecipitation and processed as in (A). (CD spectra and views of the van 
der Waals surface courtesy of Dr. Yang Daiwen, Yang Shuai and Dr. Zhang Jingfeng). 
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3.2.6 DLC1-SAM facilitates dynamic disposition of EF1A1 to cell periphery 
3.2.6.1 Effects of DLC1-SAM on actin-binding and polymerization 
EF1A1 is a multi-functional protein that regulates general protein synthesis and 
also actin and microtubule network (Thornton et al., 2003; Liu et al., 2002; Gross & 
Kinzy, 2007; Moore et al., 1998). EF1A1 regulates the actin network through its G-actin 
binding and F-actin bundling activity (Liu et al., 2002; Gross & Kinzy, 2005; Murray et 
al., 1996). Since DLC1 is a RhoGAP that acts on RhoA, which is a key regulatory switch 
for actin network, we hypothesized that DLC1’s interaction with EF1A1 could be linked 
to actin-based dynamics.  
Since the G-actin binding and F-actin bundling activity of EF1A1 had been shown 
previously (Liu et al., 2002; Gross & Kinzy, 2005; Murray et al., 1996), we set out to 
determine whether DLC1-SAM domain alone or its interaction with EF1A1 has any 
effect on the actin-binding and actin-proliferaction activity. First, we examined the in 
vitro G-actin binding activity of DLC1-SAM. Pulldown assay using purified globular 
actin (G-actin) and Flag-tagged wild type DLC1-SAM, FLF-mutant, DLC2-SAM 
expressed in 293T cells was carried out. The result shows that the wild type DLC1-SAM 
could pull down G-actin, while DLC1-SAM-FLF and DLC2-SAM could not (Figure 
3.11). The failure to pull down G-actin by the FLF mutant and DLC2-SAM indicated that  
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Figure 3.11 Interaction of DLC1-SAM with globular actin in vitro. SAM forms a 
complex with G-actin in vitro. Flag-tagged DLC1-SAM, DLC1-SAM-FLF and DLC2-
SAM expressed in 293T cells and purified on M2-anti-FLag beads were incubated with 
purified globular actin at room temperature for 1.5 hour. Proteins bound on beads with 
incubation (+) or without incubation (-) were immunoblotted with indicated antibodies. 
EF1A1 regulates actin dynamic and inhibits actin polymerization through binding 
and bundling actin filaments (Murray et al., 1996). To assess whether DLC1-SAM 
binding to EF1A1 could have any direct effect on EF1A1 activity in actin dynamic, 
pyrene-labeled actin polymerization assays were performed in the presence of purified 
GST-EF1A1 with or without equimolar of GST-DLC1-SAM (Figure 3.12A). In this assay,
fluorescence is enhanced when pyrene conjugated actin monomers associate into actin 
filaments and the steady state level of fluorecence correlates to the extent of polymerization. 
So the effects of certain compounds on actin polymerization can be indicated by the 
fluorescence level of the polymerization after adding the samples into the reaction. Samples 
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Some actin-regulating proteins affect actin polymerization only with the presence 
of the actin nucleator Actin-related protein 2/3 (Arp2/3) complex (Goley & Welch, 2006; 
Rohatgi et al., 1999). To test whether SAM will affect actin polymerization under similar 
conditions, the assays with Arp2/3 were carried out. The result shows that SAM did not 
have any direct effect on the actin polymerization catalyzed by Arp2/3 complex (Figure 
3.12A, 3.12C). These results therefore suggest that DLC1-SAM does not directly regulate 
EF1A1 activity towards actin binding and actin-polymerization. But it is still possible 
that the interaction between DLC1-SAM and EF1A1 might play a role in actin dynamic 
in intact cells instead. 
 
 
A                                











with EF1A1 all have a less steep gradient and a lower-valued plateau compared to the 
control, showing that EF1A1 could decrease actin polymerization speed and the final 
amount of polymerized actin. Such effects indicate an activity of EF1A1 in sequestering 
G-actin from actin polymerization. In comparison, SAM alone could not. Neither did 
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Figure 3.12 DLC1-SAM does not affect actin polymerization in vitro. (A) Purified 
mGST, mGST-DLC1-SAM wild type (WT), mGST-DLC1-SAM FLF mutant expressed 
in 293T cells and bGST-EF1A1 expressed in E.coli. were analyzed on SDS-PAGE and 
the protein gel was stained with Coomassie Blue to show the purity and equal amount of 
the peptides used in different samples. (B) Pyrene actin assay was performed to monitor 
the polymerization of 0.4 mg/ml pyrene-labeled G-actin in the presence of equimolar 
purified proteins as shown in (A). (C) DLC1-SAM does not affect actin polymerization in 
the presence of Arp2/3 complex. Pyrene actin polymerization was measured in the 
presence of purified mGST-DLC1-SAM wild type (WT) alone, purified Arp2/3 complex 
alone, both components added together, or no test proteins were added (-) as control. m: 
mammalian expressed; b: bacterial expressed; RFU: relative fluorescence units. 
 
3.2.6.2 SAM domain mediates dynamic disposition of DLC1 with EF1A1 on cortical 
actin and membrane ruffles 
Actin is assembled at major cellular structures such as focal adhesions, stress 
fibers, microspikes, membrane cortical and membrane ruffles (Rodriguez et al., 2003). To 
better understand the functional relationship between DLC1-SAM and EF1A1 in actin-
based cell dynamics, we used NIH3T3 cells treated with fibroblast growth factor (FGF) 
and confocal immunofluorescence microscopy to evaluate how DLC1 (wild type and 
mutants) and EF1A1 would regulate each other’s disposition in some of these actin-rich 
structures. We first observed that expression of the full-length DLC1 in NIH3T3 
fibroblasts led to drastic shrinkage of the cell body with resultant multiple protrusions. 
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These cells were also associated with major disruption at the focal adhesions. However, 
expression of DLC1-SAM or EF1A1 was never localized to the focal adhesions, as 
marked by paxillin staining in those cells, nor did it lead to drastic change of cell 
morphology, as compared with the non-transfected cell (arrows). Instead, they were 
diffused in the cytosol of the cells that still retained intact focal adhesions (Figure 3.13A). 
This result indicates that SAM domain is not required for DLC1’s effect in dissolving 
focal adhesions. 
Next, the disposition of DLC1 and EF1A1 at membrane cortical and membrane 
ruffles in quiescent and FGF-treated NIH3T3 cells were examined (Figure 3.13B). 
During quiescent state, DLC1 (wildtype or FLF) induced cell shrinkage indicative of an 
active RhoGAP. There, EF1A1 was mostly concentrated on cell periphery whereas DLC1 
appeared to be partially colocalised with EF1A1 on cell periphery or being distributed in 
some punctate structures (labeled P). By comparison, overexpression of SAM domain 
and EF1A1 did not affect the cell morphology where SAM was seen colocalised strongly 
with EF1A1 in cytosol and at cortical actin (indicated by box).  However, SAM-FLF
that did not interact with EF1A1 failed to colocalise with EF1A1 (dotted box).  To gain 
a better insight to the nature of the disposition of DLC1, the catalytic arginine-finger R677 
within the GAP domain of DLC1 was mutated to glutamic acid. This mutant (DLC1-
R677E) rendered cell spreading, thus allowing better studies of the intracellur distribution 
of these two proteins. There, the majority of DLC1-R677E was concentrated in large 
vesicular structures within the cytosol (labeled P), while EF1A1 now appeared more 
cytosolic-diffused  than  it was in the presence of a GAP-active DLC1.  However, 
no colocalization of  DLC1-R677E with EF1A1 was  observed at cell periphery. 
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Comparing to the result by the DLC1-SAM domain alone,  this  result suggests that 
despite the presence of SAM domain, the inactivation of the GAP activity caused the 
retention of DLC1 in specific subcellular compartments, thus preventing its interaction 
with EF1A1 during the quiescent state. Consistently, DLC1-R677E carrying further 
mutations on FLF motif (DLC1-R677E-FLF) presented the same results as DLC1-R677E. 
Interestingly, after FGF treatment, the DLC1 full-length, SAM and GAP-inactive 
DLC1-R677E all exhibited strong colocalization with EF1A1 in the cytosol, cortical 
region and also on the membrane ruffles (highlighted in boxes). However, introducing the 
FLF mutant to these constructs resulted in weaker if not complete loss of colocalisation of 
EF1A1 with DLC1 on these cellular structures. Indeed, EF1A1 appeared to be “retarded” 
or de-localised to the  perinuclear  and  cytosolic region (dotted boxes).  Consistantly, 
DLC2-SAM  that lacks the hydrophobic surface formed by FL residues in DLC1-SAM and 
does not bind EF1A1, did not colocalise with EF1A1 on these structures either.  
Taken together, these results indicate that upon FGF stimulation, the SAM domain 
of DLC1 facilitated EF1A1 relocalisation from the cytosol and perinuclear regions to 
the site of actin-rich membrane ruffles via its specific interaction with EF1A1. There, 
























































































Figure 3.13 DLC1-SAM domain facilitates recruitment of EF1A1 to membrane 
periphery and membrane ruffles. (A and B) NIH3T3 cells were transfected with 
various constructs and made quiescent by maintaining in medium with 0.5% serum for 19 
hours followed by treatment for 20 min with 10 ng/ml fibroblast growth factor (FGF). 
Cells were then fixed, permeabilized, stained and visualized under confocal 
immunofluorescent microcopy as described in “Materials and Methods”. (A) DLC1-SAM 
and EF1A1 do not localize to paxillin at the focal adhesions. Cells were transfected with 
either Flag-DLC1, Flag-DLC1-SAM or HA-EF1A1 and treated with FGF before fixation. 
Ectopic expression of the proteins were detected by anti-Flag or anti-HA (red), and the 
focal adhesions are shown by anti-paxillin (green), followed by appropriate fluorophore-
conjugated secondary antibodies. Merged signals are presented as overlaid staining 
(yellow). Arrow indicates untransfected control cell. (B) Cells were cotransfected with 
HA-EF1A1 and Flag-constructs of either DLC1 wild type (DLC1), DLC1 full length 
mutant F38G/L39G/F40G (DLC1-FLF), DLC1 full length mutant R677E (DLC1-R677E), 
DLC1 full length with combo-mutant of R677E and F38G/L39G/F40G (DLC1-R677E-
FLF), DLC1-SAM domain wild type (SAM), SAM domain mutant F38G/L39G/F40G 
(SAM-FLF), or DLC2-SAM domain. Co-expressed HA-EF1A1 (a; blue), and different 
Flag-DLC1 constructs (b; green) were detected by appropriate anti-Flag and anti-HA 
followed by fluorophore-conjugated secondary antibodies. Cells were labeled with 
TRITC-phalloidin (c; red) to mark cell border, the cortical actin on cell periphery or 
membrane ruffles. Merged signals are presented as overlaid staining (d; cyan for A 
overlaid with B; purple for A overlaid with C; yellow for B overlaid with C; “bright 
white” for A overlaid with both B and C). The intensities of images were enhanced to 
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capture changes in the cell peripheries and cell protrusions. Red bars indicate 10 µm. 
 
3.2.7 DLC1-SAM domain plays an auxiliary role in suppressing cell migration 
It is known that DLC1 can suppress cell migration (Goodison et al., 2005; Wong 
et al., 2005). Here, we show that its SAM domain could recruit EF1A1 to cell periphery 
and membrane ruffles. Since formation of membrane ruffles is associated with cell 
migration, we sought to determine how DLC1-SAM could impact on this important 
biological process. Boyden chamber migration assays were used to examine the effects of 
wildtype and mutant constucts on cell migration. Motile NIH3T3 cells were transiently 
transfected with GFP plasmid together with greater excess of the Flag-tagged vector (Ctrl) 
or Flag-tagged wild-type/full length DLC1 (DLC1 WT), or with full length DLC1 with 
the specific triple FLF mutations (DLC1-FLF). After 4 hours, cells were allowed to 
migrate and the proportions of all transfected cells were then scored for their ability to 
exert migration as described in “Materials and Methods”. Figure 3.14A shows that 
wildtype DLC1 greatly inhibited the rate of migration by more than 70%. However, the 
DLC1-FLF mutant displayed a significantly lower potency of inhibition compared to the 
wildtype (p=0.06). The result indicates that the interaction between EF1A1 and SAM 
domain could play a role in supporting the full suppression of cell migration by DLC1. In 
connection with this, it is predicted that introducing SAM domain could compete off the 
binding of endogenous EF1A1 with DLC1, thus affecting the intrinsic motility of these 
cells. To verify this, NIH3T3 cells were transiently transfected with GFP-tagged vector 
(Ctrl), DLC1-SAM wildtype (SAM) or SAM FLF-mutant (SAM-FLF) and allowed to 
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migrate for 4 hours. Figure 3.14B shows that cells expressing DLC1-SAM domain 
appeared to exert higher migration rate compared to the control and SAM-FLF. However, 
such stimulatory effect was only marginal probably because NIH3T3 cells already 
possessed high basal motility rate, making these cell lines best used for inhibition studies 
in cell migration as shown in Figure 3.14A. To further investigate the potentially 
stimulatory effect on cell migration by DLC1-SAM, we opted to use the epithelial MCF7 
which was less motile at the basal level but confer high stimulatory capacity when 
compared to the NIH3T3. As a further control, effects of DLC2-SAM, which is highly 
homologous to DLC1-SAM but can not interact with EF1A1, was examined. Here, 
expression of the exogenous DLC1-SAM alone increased the rate of cell migration by 
more than two-folds (p< 0.01). However, this stimulatory effect was not observed at all 
when the corresponding DLC1-SAM-FLF mutant or DLC2-SAM was introduced 
(Figure3.14C). Since NIH3T3 and MCF7 cells have endogenous DLC1 expression (data 
not shown), it is conceivable that the exogenous SAM domain might act as a dominant 
negative mutant that interrupts the interaction between endogenous DLC1 and EF1A1, 
thus reversing the suppressive effect of the endogenous DLC1.  
Taken together, our results strongly support the notion that DLC1 could mobilize 
EF1A1 to the membrane periphery and membrane ruffles via its SAM domain that could 
help establish actin-based dynamics necessary for the suppression of cell migration. Such 
auxiliary effect by SAM to the GAP-induced inhibition could serve to fine-tune the 
































Ctrl        DLC1          DLC1-FLF Ctrl      SAM    SAM-FLF






























Figure 3.14 Effects of DLC1-SAM on cell migration. (A to C) The effects of different 
constructs on cell migration were assayed in Boyden chamber. Data were presented as the 
means +/- standard deviation (SD) compared with the control of 3 to 4 independent 
experiments. Statistical comparison was made using ANOVA and Newman-Keuls 
multiple comparisons. (A) NIH3T3 cells were transfected with GFP-tagged plasmid as 
cell marker together with 2 times quantity of Flag-tagged vector (Ctrl) or Flag-tagged 
DLC1 full-length wild-type (DLC1), FLF mutant of full length (DLC1-FLF). Data 
denoted by different letters indicate significant difference at p values of < 0.06. (B) 
NIH3T3 cells were transfected with GFP-tagged vector (Ctrl) or GFP-tagged DLC1-
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SAM domain wild-type (SAM), FLF mutant (SAM-FLF). (C) MCF7 cells were 
transfected with GFP-tagged vector (Ctrl) or GFP-tagged DLC1-SAM domain wild-type 
(SAM), FLF mutant (SAM-FLF). Data denoted by different letters indicate significant 
difference at p values of < 0.02. 
 
3.3 Identifying BNIP-Sα as a novel interacting partner of DLC1 
3.3.1 Interaction of DLC1 with BCH domain-containing proteins 
As a GAP with in vitro activity specific towards RhoA and Cdc42 but not Rac1 
(Wong et al., 2003), DLC1 was reported to promote apoptosis when restoring its 
expression in HCC cells (Zhou et al., 2004). Another RhoA-interacting protein BNIP-2 
Similar isoform alpha (BNIP-Sα) was identified as a proapoptotic protein by our group, 
for which the interaction with RhoA is essential for its proapoptotic function (Zhou et al., 
2002; Zhou et al., 2006). It is worth noting that both DLC1 and BNIP-Sα are related to 
RhoA pathway and have apoptotic function. This raises an interesting issue whether both 
DLC1 and BNIP-Sα work in similar pathways. So we hypothesized that DLC1 might 
interact with BNIP-Sα. To test this hypothesis, binding studies were carried out for DLC1 
and BNIP-Sα. Immunoprecipitation assay was carried out using 293T cells co-transfected 
with HA-tagged DLC1 and Flag-tagged BNIP-Sα. BNIP-Sα contains a BNIP-2 and 
CDC42 Homology (BCH) domain at its C-terminus (Figure 3.15A). Another two Flag-
tagged proteins with similar domain organization, BNIP-2 and BNIP-2 Homology 
(BNIP-H), were also tested to compare their binding specificity towards DLC1 (Figure 
 93
3.15A). BNIP-2 can bind to Cdc42 through it BCH domain to induce cell elongation and 
membrane protrusions (Zhou et al., 2005). BNIP-H can interact with glutaminase and 
regulate its enzyme activity (Buschdorf et al., 2006). In the immunoprecipitation assay, 
an unrelated Flag-tagged control construct was used as negative control. The result shows 
that DLC1 was specifically co-immunoprecipitated by BNIP-Sα and BNIP-2, but not by 
BNIP-H or the control construct (Figure 3.15B). Since BNIP-H can bind to some of its 
interacting partners only under NGF stimulation condition in PC12 cells but not in 293T 
cells (unpublished data), binding assay of DLC1 and BNIP-H was further carried out 
under such condition by co-worker (courtesy of Chew Li Li). Consistently, the 
immunoprecipitation result shows no binding between DLC1 and BNIP-H. These results 
together show that DLC1 could specifically interact with two BCH domain-containing 
proteins, BNIP-Sα and BNIP-2. 





















































Figure 3.15 DLC1 could form complexes with BNIP-Sα and BNIP-2. (A) Schematic 
diagram showing the composition of protein domains of human BNIP-Sα, BNIP-2 and 
BNIP-H. (B) 293T cells were co-transfected with plasmids encoding HA-tagged DLC1 
and Flag-tagged BNIP-Sα, BNIP-2, BNIP-H or a control encoding an unrelated protein 
 94
(Ctrl). Whole cell lysates (WCL) were used for immunoprecipitation (IP) and incubated 
with M2-anti-Flag beads. WCL and IP samples were immunoblotted with indicated 
antibodies.  
 
3.3.2 Identifying key DLC1-interacting motif on BNIP-Sα 
3.3.2.1 BCH domain of BNIP-Sα is important for the interaction with DLC1 
Since both DLC1 and BNIP-Sα have proapototic function, we focused our 
following research on the binding between DLC1 and BNIP-Sα. We set out to look for 
important domain/motif of BNIP-Sα in the interaction with DLC1 in order to define the 
binding mechanism between BNIP-Sα and DLC1. BNIP-Sα contains one BCH domain 
in its C-terminus and no other domains or motifs are identified in its N-terminus. Our 
colleague found that BNIP-Sα interests with RhoA through its BCH domain which is 
essential for its proapoptotic function (Zhou et al., 2002; Zhou et al., 2006). We 
wondered whether BCH domain is also important for the interaction between DLC1 and 
BNIP-Sα. To address this issue, various truncation mutants of BNIP-Sα with or without 
BCH domain (Figure 3.16A) were used in the following binding studies to examine their 
affinity towards DLC1.  
First, immunoprecipitation assay was carried out using 293T cells transfected 
with Flag-tagged BNIP-Sα full length (FL), NBCH construct or CBCH construct 
together with HA-tagged DLC1 full length (Figure 3.16B). The result shows that DLC1 
interacts specifically with BNIP-Sα full length and CBCH construct, which both contain 
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BCH domain, but not with the NBCH construct without BCH domain, indicating that 
BCH domain is essential for the interaction. To confirm this, in vitro pulldown assay was 
carried out using whole cell lysate of 293T cells expressing Flag-tagged DLC1 and 
purified GST-tagged BNIP-Sα full length, N and CBCH construct expressed from 
bacteria (Figure 3.16C). Consistent with the immunoprecipitation result, the pulldown 
result shows that DLC1 can be pulled down by BNIP-Sα full length and CBCH construct, 
but not by N construct lacking BCH domain. The above results together show that the 
BCH domain of BNIP-Sα is important for the interaction with DLC1. 
1 133 275
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Figure 3.16 BNIP-Sα-BCH domain is important for the interaction with DLC1. (A) 
Schematic diagram showing the composition of protein domains of different BNIP-
Sα truncation mutants. (B) 293T cells were co-transfected with plasmids encoding HA-
tagged DLC1 and Flag-tagged BNIP-Sα full length (FL), NBCH or CBCH constructs. 
Whole cell lysates (WCL) were used for immunoprecipitation (IP) and incubated with 
M2-anti-Flag beads. WCL and IP samples were immunoblotted with indicated antibodies. 
(C) 293T whole cell lysates (WCL) expressing Flag-tagged DLC1 were used for pull-
down assay (PD) with GST-tagged BNIP-Sα full length (FL), N and CBCH constructs 
purified on glutathione-sepharose beads. GST proteins and the bound Flag-DLC1 were 
separated on SDS-PAGE, blotted and probed with anti-Flag antibodies (upper panel). 
Blot was stripped and stained with amido black to reveal loading of GST recombinants 
(bottom panel). 
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3.3.2.2 GAP-binding motif in BNIP-Sα-BCH is important for its interaction with 
DLC1 
Next, we tried to explore the possible molecular mechanism of the interaction 
between DLC1 and BNIP-Sα by examining functional motifs within the BCH domain of 
BNIP-Sα. It is known that BNIP-Sα has several binding partners, including BNIP-Sα 
itself, RhoA and p50-RhoGAP (Zhou et al., 2002). Our group had defined the molecular 
mechanism of how BNIP-Sα mediates the interactions with several targets through its 
BCH domain. Previously, we identified that residues 215-221 is the homophilic 
interaction motif of BNIP-Sα (Zhou et al., 2002). Recently, our group found out that 
there is a minimum RhoA binding region (amino acid 133-177) within the BCH domain 
of BNIP-Sα, and overlapping with this region there is a GAP-binding motif (“GBM”) 
(amino acid 133-147) necessary for the interaction of BNIP-Sα and p50-RhoGAP (Zhou 
et al., 2006). p50-RhoGAP is a RhoGAP targeting RhoA and Cdc42 (Barfod et al., 1993; 
Lancaster et al., 1994). Similarly, DLC1 has in vitro GAP activity towards RhoA and 
Cdc42 (Wong et al., 2003). So we hypothesized that the GBM region of BNIP-Sα might 
also be essential for the interaction with DLC1. Alternatively, with RhoA being the 
cognate targets of BNIP-Sα and DLC1, RhoA could possibly mediate the interaction of 
BNIP-Sα and DLC1, leading the three proteins forming a complex. To shed light on these 
various possibilities, several deletion mutants of BNIP-Sα were used for the further 
binding studies (Figure 3.17A). ∆A mutant is deleted in the RhoA binding region and 
∆A1 mutant is deleted in the GAP-binding motif within the RhoA binding region. Both of 
these two mutants lose the binding ability towards RhoA and p50-RhoGAP. ∆A2 mutant 
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is deleted in residues within the RhoA binding region but outside the GAP-binding motif, 
which can not bind to RhoA but still retains binding activity towards p50-RhoGAP. ∆B 
mutant is deleted in the homophilic interaction motif of BNIP-Sα and thus loses its self-
interacting activity. Such Flag-tagged mutant and wildtype constructs of BNIP-Sα and 
HA-tagged DLC1 full length were co-transfected in 293T cells and the whole cell lysate 
was used for immunoprecipitation assays. Surprisingly, when the cells were transfected 
with ∆A, ∆A1 or ∆A2 together with DLC1, a lot of cells died and floated up in the 
medium within 24 hours after transfection, leading to low concentration of these proteins 
in the whole cell lysate. In our attempt to achieve similar expression level of all the 
constructs, we collected the whole cell lysate for immunoprecipitation at around 16 hours 
after transfection before a large portion of the cells would die. Figure 3.17B shows the 
immunoprecipitation result when most of the constructs were expressed on similar level 
except ∆A1 mutant. The result shows that only NBCH and ∆A mutants of BNIP-Sα lost 
the binding activity to DLC1. In contrast, binding of the wildtype BNIP-Sα, ∆A2 and ∆B 
mutants with DLC1 were still intact (Figure 3.17B). It shows that constructs devoid only 
the binding activity to RhoA or the homophilic interaction activity (∆A2 and ∆B) still 
retain the interaction with DLC1, while constructs losing the p50-RhoGAP binding 
activity in addition to RhoA-binding activity (∆A) lost the interaction with DLC1. 
Together the results suggest that the p50-RhoGAP-binding motif of BNIP-Sα is essential 
for the interaction with DLC1.  
In order to confirm that the loss of binding between ∆A mutant and DLC1 was not 
due to the detrimental effect on cells caused by co-expressing these two proteins, an in 
vitro binding assay was performed using cell lysate of single transfected 293T cells, 
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under which condition most of the cells were not floating up. Cells were first transfected 
with either HA-tagged DLC1, Flag-tagged wildtype BNIP-Sα or Flag-tagged ∆A mutant. 
Then equal amount of cell lysate expressing HA-tagged DLC1 was mixed with cell lysate 
expressing Flag-tagged BNIP-Sα wild type or ∆A mutant respectively. Later the HA-
DLC1 bound to BNIP-Sα was examined by anti-Flag immunoprecipitation and Western 
Blotting. The result shows that BNIP-Sα wild type could still interact with DLC1, while 
∆A mutant did not show any interaction with DLC1 (Figure 3.17C). It shows that the loss 
of binding is not a result of cell death or unhealthy growth condition, confirming that 
deletion of the entire RhoA binding region in BCH domain results in the loss of 
interaction between BNIP-Sα and DLC1. Binding assays of Figure 3.17B and 3.17C 
together shows that the GAP-binding motif in BCH domain of BNIP-Sα is essential for 
the interaction with DLC1. 
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Figure 3.17 GAP-binding motif in BCH domain is important for the interaction with 
DLC1. (A) Schematic diagram showing the composition of protein domains and 
functional motifs of different BNIP-Sα deletion mutants. Numbers in the brackets 
indicate the deleted amino acid sequences. (B) 293T cells were co-transfected with 
plasmids encoding HA-tagged DLC1 and Flag-tagged BNIP-Sα full length (FL), NBCH, 
∆A, ∆B or ∆A2 constructs. Whole cell lysates (WCL) were used for immunoprecipitation 
(IP) and incubated with M2-anti-Flag beads. WCL and IP samples were immunoblotted 
with indicated antibodies. (C) 293T cell lysates expressing Flag-tagged BNIP-Sα full 
length (FL) or ∆A mutant were mixed with cell lysates expressing HA-DLC1 for 2 hours 
before incubation with M2-anti-Flag beads for another 2 hours for immunoprecipitation 
(IP). 10% lysate and IP samples were immunoblotted with indicated antibodies. 
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3.3.3 Identifying key BNIP-Sα-interacting motifs on DLC1 
3.3.3.1 Multiple regions in DLC1 are involved in binding to BNIP-Sα 
In our attempt in elucidating the interaction mechanism between DLC1 and 
BNIP-Sα, we continued to investigate key BNIP-Sα-interacting motifs on DLC1. DLC1 
is a large protein with 1091 amino acid. So we made various truncation mutants 
containing different domains/regions of DLC1 for the following binding studies (Figure 
3.18A). N mutant is the N-terminus fragment consisting of the SAM domain and the 
region between SAM domain and GAP domain of DLC1 (it is named as P region 
thereafter). GC mutant is the C-terminus fragment consisting of the GAP domain and the 
START domain. C mutant includes the START domain and the region between the GAP 
domain and the START domain (it is named as R region thereafter). Immunoprecipitation 
assays were carried out using whole cell lysate of 293T cells transfected with Flag-tagged 
BNIP-Sα full length together with various HA-tagged DLC1 truncation mutants (Figure 
3.18B). N mutant, GC mutant and C mutant were co-immunoprecipitated by BNIP-Sα. 
Meanwhile, neither SAM domain nor GAP domain was co-immunoprecipitated by BNIP-
Sα, even though their expression level is much higher than N, GC or C mutants. One 
interpretation of the result would be that there may be multiple interacting sites in DLC1 
towards BNIP-Sα, at least one in the P region and one in R region or the START domain, 
either contributing to direct binding to BNIP-Sα or mediating the binding through an 
unknown third partner, possibly RhoA. An alternative explanation would be that the 
binding of either region is nonspecific. In order to confirm the binding specificity of N-
terminus and C-terminus of DLC1 with BNIP-Sα, co-immunoprecipitation assays were 
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performed using HA-tagged N mutant or GC mutant of DLC1 co-expressed with Flag-
tagged BNIP-Sα full length, NBCH mutant or CBCH mutant. Here NBCH construct was 
used as a negative control, since DLC1 full length did not bind to NBCH (as shown in 
Figure 3.16B). Figure 3.19A and Figure 3.19B show that neither N mutant nor GC mutant 
bound to NBCH mutant of BNIP-Sα, while both of them bound to BNIP-Sα full length 
and CBCH mutant, which is consistent with the binding specificity of DLC1 full length. 
The results confirm the specificity for the binding activity in the N terminus and C 
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Figure 3.18 Multiple regions in DLC1 are involved in the binding to BNIP-Sα. (A) 
Schematic diagram showing the composition of protein domains of different DLC1 
truncation mutants. (B) 293T cells were co-transfected with plasmids encoding Flag-
tagged BNIP-Sα full length and HA-tagged DLC1-N, SAM, GC, GAP or C constructs. 
Whole cell lysates (WCL) were used for immunoprecipitation (IP) and incubated with 
M2-anti-Flag beads. WCL and IP samples were immunoblotted with indicated antibodies. 
Asterisk indicates heavy chains of the anti-Flag antibody on the M2-beads. 
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Figure 3.19 Both DLC1-N terminus and -C terminus specifically target BNIP-Sα-
BCH domain. (A and B) 293T cells were co-transfected with plasmids encoding HA-
tagged DLC1-N (A) or DLC1-GC (B) constructs and Flag-tagged BNIP-Sα full length 
(FL), NBCH mutant or CBCH mutant. Whole cell lysates (WCL) were used for 
immunoprecipitation (IP) and incubated with M2-anti-Flag beads. WCL and IP samples 
were immunoblotted with indicated antibodies.  
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3.3.3.2 DLC1-START domain has binding affinity towards BNIP-Sα 
Our results show that the C-terminus of DLC1 has binding affinity towards the 
BCH domain of BNIP-Sα. BCH domain might have putative lipid-binding property since 
it share low degree of homology with the lipid-binding Sec14 domain (Low et al., 
2000A). Noticeably, there is a START domain located at the C-terminus of DLC1, which 
is also a putative lipid binding domain (as introduced in Chapter 1). DLC1- START 
domain could be involved in phospholipid pathways since the DLC1 mouse homologue, 
p122RhoGAP, could bind to PLCδ1, an enzyme for phospholipid PIP2, and the C-
terminus containing START domain is responsible for the activation of PLCδ1 by 
p122RhoGAP (Homma & Emori, 1995; Sekimata et al., 1999). It is possible that lipid 
molecules might help bring the BNIP-Sα−BCH domain or DLC1-START domain into 
proximity. Thus, we raised our hypothesis that DLC1-START domain might be the 
binding site in the C-terminus for BNIP-Sα. To verify our hypothesis, we examined the 
binding activity of START domain towards BNIP-Sα. DLC1 truncation mutants 
containing different parts of the C-terminus were constructed and used for the following 
binding study (Figure 3.20A). Co-immunoprecipitation assay was carried out using 293T 
cells transfected with HA-tagged GR or START constructs of DLC1 together with Flag-
tagged BNIP-Sα. The result shows that only START constructs not GR constructs was 
immunoprecipitated by BNIP-Sα, even though the expression level of GR was much 
higher than START (Figure 3.20B). Here, we show that the putative lipid-binding domain, 
START domain, is the C-terminal binding site of DLC1 towards BNIP-Sα. It is not clear 
whether their binding is direct or mediated by a third partner, possibly lipids. This will 
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need more detailed future investigation. Currently, the lipid-binding property of BNIPSa 
BCH domain is under investigation. The significance of such interaction will be 
discussed in chapter 4.  
A                                           
DLC1-GC
GAP START
652          798      886                           1091
GR: 652-882
START: 886-1091  
B 
HA:  GR START  GR START








Figure 3.20 The START domain of DLC1 has affinity towards BNIP-Sα. (A) 
Schematic diagram showing the composition of protein domains of different DLC1-C 
terminus truncation mutants. (B) 293T cells were co-transfected with plasmids encoding 
HA-tagged DLC1-GR or DLC1-START constructs and Flag-tagged BNIP-Sα full length. 
Whole cell lysates (WCL) were used for immunoprecipitation (IP) and incubated with 
M2-anti-Flag beads. WCL and IP samples were immunoblotted with indicated antibodies.  
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3.3.3.3 DLC1-P1 and P3 sequences have binding affinity towards BNIP-Sα 
We also show that the N-terminus of DLC1 has binding affinity towards the BCH 
domain of BNIP-Sα and the linker region between SAM domain and GAP domain (P 
region) on DLC1 could be the binding site since DLC1-SAM does not bind to BNIPSα. 
DLC1-P region contains around 570 amino acids in it. Although no conserved domain 
could be identified in such a long sequence, the corresponding sequences of DLC2 and 
DLC3 are quite conserved with 48% and 29% identity with DLC1-P region respectively 
(Durkin et al., 2007B). It raises our hypothesis that P region might play a role in the 
function of DLC1. Our current data showing the binding capacity of DLC1-P region 
towards BNIP-Sα supports our hypothesis (Figure 3.18B). To explore the function of P 
region, we continued to investigate the binding mechanism of DLC1-P towards BNIPSα 
through identifying shorter binding region within the long sequence of DLC1-P. To do 
this, we first made smaller truncation mutants of P region for the following binding study. 
Three truncation mutants, P1, P2 and P3, were generated according to the predicted 
secondary structure of P region (Figure 3.21A). The truncation sites of the mutants were 
designed in the predicted random coiled region to avoid spoiling any helice or beta strand 
structure. We continued to examine the binding affinity of DLC1-P1, P2 and P3 towards 
BNIP-Sα with co-immunoprecipitation assays. HA-tagged P, P1, P2 or P3 construct was 
transfected together with Flag-tagged BNIP-Sα or an unrelated Flag-tagged control 
construct in 293T cells. Immunoprecipitation assays show that only DLC1-P, P1 and P3 
could be co-immunoprecipitated by BNIP-Sα, but not DLC1-P2 (Figure 3.21B). None of 
the P region mutants was co-immunoprecipitated by the Flag-tagged control protein 
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(Figure 3.21C), showing the specificity of the binding results. The results indicate that 
there might be two more motifs in the N-terminus having binding affinity towards BNIP-
Sα in addition to the START domain on DLC1.  
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A 
                  80        90       100       110       120       130       140 
                   |         |         |         |         |         |         | 
DLC1-P          LEISPHRKRSDDSDEDEPCAISGKWTFQRDSKRWSRLEEFDVFSPKQDLVPGSPDDSHPKDGPS 
Sec.Cons.       eeccccccccccccccccce?ccceeecccccc??hhhcccccccccccccccccccccccccc 
 
                 150       160       170       180       190       200       210 
                   |         |         |         |         |         |         | 
DLC1-P    PGGTLMDLSERQEVSSVRSLSSTGSLPSHAPPSEDAATPRTNSVISVCSSSNLAGNDDSFGSLPSPKELS 
Sec.Cons. ccccehch?hhhh?eeeeeecccccccccccccccccccccceeeeeecccccccccccccccccccccc 
 
                 220       230       240       250       260       270       280 
                   |         |         |         |         |         |         | 
DLC1-P    SFSFSMKGHEKTAKSKTRSLLKRMESLKLKSSHHSKHKAPSKLGLIISGPILQEGMDEEKLKQLSCVEIS 
Sec.Cons. ceeeeccccccc?hhhhhhhhhhhhhhhhccccccccccccceeeeecccchh?cchhhhhhhhhheeee 
 
                 290       300       310       320       330       340       350 
                   |         |         |         |         |         |         | 
DLC1-P    ALNGNRINVPMVRKRSVSNSTQTSSSSSQSETSSAVSTPSPVTRTRSLSACNKRVGMYLEGFDPFNQSTF 
Sec.Cons. hccccccc??eece?cccccccccccccccccccccccccccc???c?ccccccceeeeccccccccccc 
 
                 360       370       380       390       400       410       420 
                   |         |         |         |         |         |         | 
DLC1-P    NNVVEQNFKNRESYPEDTVFYIPEDHKPGTFPKALTNGSFSPSGNNGSVNWRTGSFHGPGHISLRRENSS 
Sec.Cons. chhhhhccccccccccceeeeeccccccccccccccccccccccccceeeeeccccccccceeecccccc 
 
                 430       440       450       460       470       480       490 
                   |         |         |         |         |         |         | 
DLC1-P    DSPKELKRRNSSSSMSSRLSIYDNVPGSILYSSSGDLADLENEDIFPELDDILYHVKGMQRIVNQWSEKF 
Sec.Cons. ccc?hhh?ccccccccceeeeeccccceeeeccccchhhhcccccchhhhhhhhhh?c?hhhhhhhhh?c 
 
                 500       510       520       530       540       550       560 
                   |         |         |         |         |         |         | 
DLC1-P    SDEGDSDSALDSVSPCPSSPKQIHLDVDNDRTTPSDLDSTGNSLNEPEEPSEIPERRDSGVGASLTRSNR 
Sec.Cons. cccccccccccccccccccccceeeeccccccccccccccccccccccccccccccccccccc?e?cccc 
 
                 570       580       590       600       610       620       630 
                   |         |         |         |         |         |         | 
DLC1-P    HRLRWHSFQSSHRPSLNSVSLQINCQSVAQMNLLQKYSLLKLTALLEKYTPSNKHGFSWAVPKFMKRIKV 
Sec.Cons. c?eeeecccccccccccceeeeeccchhhhhhhhhhhhhhhhhhhhhhcccccccccccc?hhhhhhe?c 
 
                 640       650   
                   |         |   




h: Alpha helix     e: Extended strand     c: Random coil    ?: Ambigous states  
DLC1-N
SAM
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Figure 3.21 DLC1-P1 and DLC1–P3 region has affinity towards BNIP-Sα. (A) The 
NPS@ (Network Protein Sequence @nalysis) consensus secondary structure prediction 
(http://npsa-pbil.ibcp.fr) was used to predict the secondary structure of DLC1-P region 
(a.a. 77-652). Only the secondary structure consensus prediction is shown here. Based on 
the prediction result, three truncation mutants were made for DLC1-P region. Schematic 
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diagram shows the composition of protein domains and the corresponding amino acid 
sequences of different DLC1-P region truncation mutants. (B and C) 293T cells were co-
transfected with plasmids encoding HA-tagged DLC1-P, P1, P2 or P3 constructs and 
Flag-tagged BNIP-Sα full length (B) or a control encoding an unrelated protein (Ctrl) (C). 
Whole cell lysates (WCL) were used for immunoprecipitation (IP) and incubated with 
M2-anti-Flag beads. WCL and IP samples were immunoblotted with indicated antibodies. 
Asterisk indicates heavy chains of the anti-Flag antibody on the M2-beads. 
 
3.3.3.4 Deletion in DLC1-P3 lost the function in changing cell morphology  
Our binding studies together show that 3 regions on DLC1 have binding affinity 
towards BNIP-Sα and the GAP-binding motif on the BCH domain of BNIP-Sα is 
essential for their interaction (Figure 3.22). Morphological changes are closely linked to 
cellular functions. Since full length DLC1 can cause drastic morphological changes of 
cells (rounding of cell bodies and protruding long and thin “beads-on-a-string structures” 
accompanied by disruption of stress fibers and dissociation of focal adhesions) (Figure 
3.13A, 3.13B), we examined whether deletion of any BNIP-Sα-interacting region on 
DLC1 (Figure 3.23A) could impact on the function of DLC1 on cellular morphology in 
order to investigate the functional importance of such regions. NIH3T3 cells transfected 
with wildtype DLC1 or the deletion mutants were fixed, immunostained for the 
overexpressed proteins and observed under fluorescence microscope. Cells were also 
immunostained for focal adhesion protein Paxillin to show intact focal adhesion 
structures. NIH3T3 cells were used here because they have clear stress fiber and focal 
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adhesion structures. Figure 3.23B shows that both ∆P1 and NG constructs as well as full-
length DLC1 could cause rounding of cell bodies and dissociation of focal adhesions 
when compared with the control untranfected cell. In contrast, cells tranfected with ∆P3 
mutant retained normal cell morphology and intact focal adhesions (short arrows). 
Furthermore, the majority of ∆P3 protein was concentrated in large vesicular structures 
within the cytosol (labeled P), while DLC1 full length, ∆P1 and NG proteins were 
diffused in the cytosol. The results suggest that deletion of P3 region strongly affects the 
function of DLC1. While the functional significance of P1 region and START domain 
remained to be deciphered in future research, we focused on P3 region in our following 
study to further investigate its role in the function of DLC1.  
 










Figure 3.22 Schematic diagrams showing the regions on DLC1 and BNIP-Sα with 




















Figure 3.23 Effects on cell morphology of DLC1 mutants deleted in different BNIP-
Sα-interactive regions. (A) Schematic diagram showing the composition of protein 
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domains of DLC1 mutants deleted in different BNIP-Sα regions. Numbers in the brackets 
indicate the deleted amino acid sequences. (B) DLC1-∆P3 could not induce cellular 
morphology changes as full length DLC1. NIH3T3 untransfected cells (Ctrl) and cells 
transfected with either Flag-tagged DLC1 full length, ∆P1, ∆P3 or NG mutants were 
fixed, permeabilized, stained and visualized under fluorescent microcope. Ectopic 
expression of the proteins were detected by anti-Flag (red), and the focal adhesions are 
shown by anti-paxillin, followed by appropriate fluorophore-conjugated secondary 
antibodies (green). Merged signals are presented as overlaid staining (yellow). Short 
arrows indicate focal adhesions. P labels indicate large vesicular structures within the 
cytosol of DLC1-∆P3. White bars indicate 10 µm. 
 
3.3.3.5 DLC1-P3 was strongly enriched by BNIP-Sα in in vitro direct binding 
We show that deletion in DLC1-P3 region leaded to the lost of function of DLC1 
protein in changing cell morphology. We also show that DLC1-P3 had binding affinity 
towards BNIP-Sα in immunoprecipitation assay (Figure 3.21). It leads to our speculation 
whether such functional importance of P3 is due to its interacting activity with BNIP-Sα. 
Meanwhile, it was not clear whether such interacting activity is direct or indirect. To 
elucidate this, in vitro direct binding study for P3 and BNIP-Sα was carried out by 
coworker of our group (courtesy of Teo Ai Shi, Valerie). The TNT Quick Coupled 
Transcription/Translation system was used to produce DLC1-P3 peptide so that it could 
be soluble and functional with correct folding from the mammalian translation machinery, 
and be more pure for the direct binding study from this cell-free system. The DLC1-P3 
peptide was then subject to GST-tagged BNIP-Sα expressed from bacteria and purified 
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on glutathione beads. Figure 3.24A shows that DLC1-P3 was specifically pulled down by 
GST-BNIP-Sα but not by GST control and it was greatly enriched by BNIP-Sα, 
indicating that the interaction between P3 and BNIP-Sα is direct and strong. To confirm 
the binding specificity, we continued to test the direct binding activity of DLC1-P3 with 
GST-tagged BNIP-Sα full length (FL), NBCH and CBCH (Figure 3.24B). The result 
shows that P3 was greatly enriched by CBCH as much as by BNIP-Sα full length. 
Meanwhile, a smaller amount of P3 was pulled down by NBCH, which is probably due to 
non-specific binding. The specificity in the in vitro direct binding between P3 and BNIP-
Sα-CBCH is consistent with our previous in vivo immunoprecipitation result between 
DLC1-N and BNIP-Sα (Figure 3.24A). Altogether, the binding results prove that P3 
region in the N-terminus of DLC1 protein mediates direct and strong interaction with the 

























































Figure 3.24 DLC1-P3 directly binds to BNIP-Sα-BCH in vitro. (A and B) HA-tagged 
P3 produced in TNT Quick Coupled Transcription/Translation system was used for pull-
down assay (PD) with GST constructs purified on glutathione-sepharose beads: (A) GST 
or GST-tagged BNIP-Sα full length; (B) GST-tagged BNIP-Sα full length (FL), NBCH 
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and CBCH. GST proteins and the bound HA-P3 were separated on SDS-PAGE, blotted 
and probed with anti-HA antibodies (upper panel). Blot was stripped and stained with 
amido black to reveal loading of GST recombinants (bottom panel). (Results courtesy of 
Teo Ai Shi, Valerie) 
 
3.4 DLC1-P3 is important for the function of DLC1 
3.4.1 DLC1-∆P3 and DLC1-R677E have similar effect in cell morphology 
Our previous microscopy study shows that deletion in DLC1-P3 lost the function 
of full length DLC1 in causing cell body shrinkage and dissociation of focal adhesions. 
To confirm the strong impact to DLC1 caused by the deletion in P3 region, we continued 
to use confocal microscope to investigate the effect on stress fibers of DLC1-∆P3. 
NIH3T3 cells were transfected with full-length DLC1 or DLC1-∆P3, fixed, 
immunostained and observed under confocal microscope. Cells were also stained with 
TRITC-phalloidin to show actin structures. Consistent with Figure 3.22B, ∆P3 protein 
was concentrated in large vesicular structures within the cytosol (label P) in most of the 
cells expressing ∆P3, while the cells retain intact stress fibers (Short arrows) (Figure 
3.25). Interestingly, such puntate distribution and lose of function of ∆P3 protein is 
similar to the GAP-negative mutant DLC1-R677E (Figure 3.13B). The RhoGAP activity 
of DLC1 was known to be essential for its function in inducing cell shrinkage and 
dissociation of stress fibers and focal adhesions (Wong et al., 2005). The similar effect of 
the two mutants raises the issue whether P3 region could regulate the function of DLC1 















Figure 3.25 DLC1-∆P3 could not induce stress fiber dissociation and cell shrinkage 
as DLC1 full length. NIH3T3 cells transfected with Flag-tagged DLC1 full length or 
∆P3 constructs were fixed, permeabilized, stained and visualized under confocal 
immunofluorescent microcopy as described in “Materials and Methods”. Ectopic 
expression of the proteins were detected by anti-Flag (green) followed by fluorophore-
conjugated secondary antibodies. Cells were stained with TRITC-phalloidin (red) to label 
actin structures. Merged signals are presented as overlaid staining (yellow). Short arrows 
indicate intact stress fibers in transfected cells. P labels indicate large vesicular structures 
of DLC1-∆P3 within the cytosol. Red bars indicate 10 µm. 
 
3.4.2 DLC1-∆P3 retains in vivo GAP activity towards RhoA  
As cellular morphological changes caused by DLC1 (shrinkage of cell body and 
disruption of stress fibers and focal adhesions) are an indication of an active RhoGAP 
function, lost of function by deletion of P3 region indicates its role in regulating the 
RhoGAP function of DLC1. To address this issue, we compared the in vivo GAP activity 
of full length DLC1 and DLC1-∆P3 towards RhoA in cells. Pull-down assay with GST-
tagged RBD domain of rhotekin was used here to examine the endogenous RhoA activity 
of various DLC1 constructs. Rhotekin is an effector of RhoA. Its RBD domain can 
recognize and specifically bind to GTP-bound RhoA. Thus the in vivo activity of RhoA 
can be determined by its magnitude of binding to GST-RBD (Ren et al., 1999; Wheeler 
and Ridley, 2004; Shang et al., 2003). 293T Cells were transfected with Flag-tagged 
DLC1 full length (FL), ∆P3, R677E (GAP negative mutant), GC (N-terminal truncation 
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mutant), ∆SAM, or remained untransfected. Cells were also transfected with GFP-tagged 
wild-type BPGAP1 (WT) or its GAP negative mutant BPGAP1-A2, for which  their GAP 
activity towards RhoA have been shown in GST-RBD pull down assay by our group  
(Shang et al., 2003). Here the BPGAP1 constructs were used as controls for the assay. 
Cell lysates expressing various constructs were then mixed with GST-RBD purified on 
glutathione beads. The amount of endogenous GTP-bound RhoA pulled down by GST-
RBD was then shown by SDS-PAGE and immunoblotting against RhoA. Figure 3.26 
shows that BPGAP1 reduced the level of endogenous active RhoA, while cells 
expressing its GAP-negative mutant BPGAP1 A2 had more active RhoA, which level is 
similar to the level in the untranfected cells. Similarly, DLC1 full length reduced active 
RhoA level, showing its active GAP function towards RhoA. Consistently, DLC1-R677E 
mutant did not have active GAP function due to the mutation on the essential “Arginine 
finger”. At the same time, SAM-deletion did not affect the GAP activity of DLC1. 
Surprisingly, what is different from our hypothesis is that ∆P3 could reduce GTP-RhoA 
to similar extent as DLC1 full length, showing that deletion in P3 region did not affect 
the RhoGAP activity directly. Interestingly, N-terminal deletion mutant (GC) lost its GAP 
activity, indicating unidentified regulatory module(s) in the N-terminus affecting the GAP 











































Flag-DLC1          GFP-BPGAP1
 
 121
Figure 3.26 The in vivo GAP activity of different DLC1 mutants towards 
endogenous RhoA. Untransfected 293T cells or cells transfected with Flag-tagged DLC1 
full length (FL), ∆P3, R677 (GAP negative mutant), GC or ∆SAM mutants, or GFP-
tagged BPGAP1 full length, GFP-tagged BPGAP1 A2 (GAP negative mutant) were used 
for pull-down assay (PD) with GST-tagged RBD purified on glutathione-sepharose beads. 
Proteins in the whole cell lysate (WCL) and the pull-down complex were processed with 
SDS-PAGE and immunoblotting. Endogenous RhoA, ectopic expression of Flag-tagged 
or GFP-tagged proteins in the whole cell lysate and the active RhoA pulled down by 
GST-RBD were immunoblotted with indicated antibodies. Blot was stripped and stained 
with amido black to reveal loading of GST-RBD 
 
3.4.3 Deletion in DLC1-P3 strongly affects its ability to suppress cell migration 
DLC1 was known for its inhibitory function in cell migration and tumor 
metastasis (Goodison et al., 2005).  Cell migration is a biological process accompanied 
by dynamic changes of cytosketon and cell morphology. The phenomenon that deletion in 
DLC1-P3 lost the function of DLC1 in causing cell morphological changes (Figure 3.23B 
and 3.25) raises an interesting issue whether deletion in DLC1-P3 could also affect its 
suppressing function in cell migration. Boyden chamber migration assay was carried out 
to address this issue. Motile NIH3T3 cells were transiently transfected with cell marker 
pCMV-βGAL alone (Ctrl) or together with 4 times quantity of the wild-type/full length 
DLC1, the P3 deletion mutant (∆P3), the N-terminal truncation mutant which contain the 
GAP domain and the START domain (GC) and the full length DLC1 GAP-negative 
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mutant (DLC1-R677E). Then the cells were allowed to migrate through a Boyden 
chamber for 12 hours. The proportions of all transfected cells were then scored for their 
ability to exert migration in 3 independent assays as described in “Materials and 
methods”. Figure 3.27 shows that wild type DLC1 greatly inhibited the rate of migration 
by more than 70%. Meanwhile, GC construct, which is deleted in the entire N-terminus 
and does not have active GAP activity towards RhoA (Figure3.26), had lost the ability to 
suppress cell migration (P<0.05). In comparison, while DLC1-Arg677 is not as potent as 
full length in suppressing cell migration, Arg677 could still inhibit the cell migration by 
around 30%, though both Arg677 and GC lost GAP activity towards RhoA (Figure 3.26). 
The difference in their suppressing ability indicates that besides the GAP domain, an 
unidentified motif in the N-terminal region of DLC1 seems to play a role in the inhibition 
in cell migration. Consistent with this, DLC1-∆P3, which retains in vivo GAP activity 
towards RhoA (Figure3.26), is greatly less potent in suppressing cell migration compared 
to full length DLC1 but could still inhibit cell migration but only by around 30% (Figure 
3.27). It shows that the lost of function in cell morphological changes by P3-deletion 
could result in the decreased ability of DLC1 in migration suppression. Taken together, 
all these results strongly support the notion that P3 region is important to the function of 
DLC1 and P3 region collaborates with the GAP activity of DLC1 in the suppression of 







































Figure 3.27 Effects of different DLC1 mutants on cell migration. NIH3T3 cells were 
transiently transfected with cell marker pCMV-βGAL alone (Ctrl) or together with 4 
times quantity of Flag-tagged DLC1 full length, ∆P3, GC or R677 (GAP negative) 
mutants. The effects of different constructs on cell migration were assayed in Boyden 
chamber. Data were presented as the means +/- standard deviation (SD) compared with 
the control of 3 independent experiments. Statistical comparison was made using 
ANOVA and Newman-Keuls multiple comparisons. Data denoted by different letters 








4.1 A novel function for the SAM domain of DLC1  
SAM domain represents an emerging class of important protein domain 
superfamily in which different members have been implicated in diverse cellular 
functions (Qiao and Bowie, 2005). The number of encoded SAM domains (in brackets) 
roughly correlates with the complexity of genomes in S. cerevisiae (4), C.elegans (26), D. 
melanogaster (42), mice (178) and the humans (206). It could serve as a docking site for 
kinase (e.g. ETS-1 transcriptional activator for ERK2 MAP kinase), as a polymeric device 
(e.g. for transcriptional repression function of TEL), as a RNA-binding domain (e.g. 
Smaug), or as a signaling scaffold through homophilic interactions (e.g. for Byr2 
serine/threonine kinase, Eph receptor tyrosine kinase and diacylglycerol kinase). Some 
SAM domains also engage non-SAM proteins as their binding partners (e.g. interaction of 
BAR with Bcl-2 and Bcl-XL) (Qiao and Bowie, 2005). Given the uniformity in structural 
folds but diversity in their functions (Kim and Bowie, 2003), our understanding on the 
precise role(s) of more than 200 SAM domains possibly encoded by the human genome 
would require systematic and thorough examinations. 
Combining proteomics, biochemical, structural and cellular studies, our current 
work had added yet another important aspect of SAM function for DLC1, a RhoGAP 
protein and a candidate tumor suppressor where it interacts specifically with an emerging 
multi-functional protein, the translational elongation factor EF1A1. Such interaction is 
specific and important as it provides the molecular basis for shuttling EF1A1 to 
membrane periphery and membrane ruffles upon FGF stimulation where it helps regulate 
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cell migration. In strong contrast, the homologous DLC2-SAM does not have any of such 
effects. This novel functional coupling immediately places the importance of DLC1-SAM 
in the context of actin-based cell dynamics control (as discussed below).  
 
4.2 The molecular mechanism of the interaction between DLC1-SAM and EF1A1 
DLC1- and DLC2-SAM adopts a unique fold with 4 nearly parallel helices, 
whereas most SAM domains consist of 5 helices organized in a globular manner. In this 
regard, we showed that DLC1-SAM does not self-associate. Instead, it utilizes mainly a 
unique hydrophobic patch to interact with EF1A1. Since DLC1-SAM does not bear 
significant resemblance to most of the other SAM domains (Figure 3.3A), it is possible 
that such sequence variability could give rise to target specificity as evidenced by the 
unique EF1A1-targeting dipeptide F38-L39 motif present only in the DLC1-SAM. 
Interestingly, when DLC1-SAM or the EF1A1 were expressed as bacterial 
recombinants they failed to interact with one another. Instead, it required either one or 
both of them being expressed in eukaryotic cells. It seems likely that such interaction 
requires certain modification(s) on at least one of the two proteins. Furthermore, both the 
GTP-binding domain (Domain I) and the actin-binding domain (Domains I and III) of 
EF1A1 are important for its interaction with DLC1-SAM. Intriguingly, the binding by the 
GTP-binding domain is only apparent in vivo and it binds stronger than the full length 
EF1A1 or the actin-binding domain III. In contrast, only the actin-binding domain III of 
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EF1A1 interacts most strongly in vitro. The apparent dynamic nature of interaction is 
likely to be due to proper folding of EF1A1 in the Eukaryotic system or extrinsic 
regulation of EF1A1 in vivo through further conformational modifications. Several 
modifications of EF1A1 have been reported previously, including methylation and 
phosphorylation at different sites on the protein. Methylation of EF1A or its prokaryote 
homologue EF-Tu was reported in several species, including E.coli., the fungus Mucor, 
mouse and rabbit.  In contrast to the single  methylation site in the prokaryote EF-Tu, 
methylation on multiple sites of EF1A was observed in eukaryote cells. The extent of 
methylation on eEF1A changes during different developmental stages and is different 
between SV40-transformed 3T3B and normal 3T3B mouse cells, suggesting methylation 
may be a novel mode of regulation of eEF1A activity or its interaction with G-actin, and a 
way to affect cell growth properties (Polevoda and Sherman, 2007). Phosphorylation of 
EF1A by several proteins was also reported as another potential way to regulate its 
activity. The F-actin-bundling activity of EF1A1 can be down-regulated as a result of 
direct phosphorylation on eEF1A1 by Rho-kinase, an important regulator of cytoskeleton 
and cell motility (Izawa et al., 2000). C-Raf, a protein involved in the Ras antiapoptotic 
pathway, can bind to eEF1A and phospohorylate eEF1A on serine and threonine residues. 
Such phosphorylation was suggested in mediating the antiapoptotic effect of C-Raf 
(Lamberti et al., 2007). Threonine phosphorylation on eEF1A1 by protein kinase Cδ was 
also reported, though the functional significance is unclear (Kielbassa et al., 1995). 
Likewise, previous studies had shown that certain SAM domains are subjected to 
phosphorylation and also modification via the small ubiquitin-like modifiers (SUMO) 
 127
(Qiao and Bowie, 2005). Previous research together implicates that the variation of the 
modifications on EF1A1 in different cell physiology is a means of regulation to its 
cellular function. Consequently, the involvement of at least two distinct domains of 
EF1A1 suggest that while F38-L39 being the essential motif (possibly by initiating the 
interaction), it is plausible that other secondary binding sites on the SAM domain could 
still well exist to render further stabilization. 
         Notably, EF1A1 has a homologue, EF1A2, which is very similar to EF1A1 on amino-
acid sequence, molecular weight and the function of peptide chain elongation in protein 
synthesis (Thornton et al., 2003). At the same time, they have different expression profiles 
(Knudson et al., 1993), indicating that they might have different cellular roles. Thus it  would 
be interesting to investigate the binding activity of DLC1-SAM towards EF1A2, which might
shed light on the binding mechanism for EF1A1 towards DLC1-SAM, and help identify the 
specific functions of these two homologues. All these results imply a complex regulation 
of EF1A1 function and interaction, the mechanism of which awaits more detailed 
structural and mutational studies.  
 
4.3 Implications of DLC1 interacting with EF1A1, a central regulator for cell 
metabolism and signaling  
This study identified EF1A1 as the interacting partner of the SAM domain of 
DLC1, and suggested that SAM domain could regulate the function of DLC1 in cell 
dynamic control through the interaction with EF1A1. The results show for the first time 
that SAM domain of DLC1 binds specifically to EF1A1. Since DLC1 is a tumor 
suppressor, their interaction supports previous hypothesis that EF1A1 might be involved 
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in tumorigenesis and exert some unknown functions besides its well-known 
house-keeping function in protein translation elongation (Lamberti et al., 2004). 
      Besides its earlier established role in transferring aminoacyl-tRNA to ribosome 
during protein synthesis (Lamberti et al., 2004; Thornton et al., 2003), EF1A1 has been 
shown to be involved either directly or indirectly in diverse cellular processes. These 
range from embryogenesis (Krieg et al., 1989), oncogenic transformation (Tatsuka et al., 
1992), mitosis (Kuriyama et al., 1990), cell proliferation (Gangwani et al., 1998), 
transporting mRNA (Liu et al., 2002), bundling of F-actin (Gross et al., 2005), controlling 
microtubule dynamics (Moore et al., 1998), conferring susceptibility to cell death induced 
by palmitate-overload (Borradaile et al., 2006) or by hydrogen peroxide (Chen et al., 
2000), as well as conferring cyto-protection against ER stress-induced apoptosis 
(Talapatra et al., 2002). Interestingly, EF1A1 also interacts with a zinc finger protein 
ZPR1 and both are co-translocated to the nucleus in response to EGF stimulation or 
nutrient stimulation to regulate normal cellular proliferation (Gangwani et al., 1998), 
whereas plant EF1A1 acts as an activator of phosphatidylinositol 4-kinase (Yang et al., 
1993; Yang and Boss, 1994). Furthermore, EF1A1 binds to the split-Pleckstrin Homology 
domain of phospholipase Cγ1 to regulate IP3 production (Chang et al., 2002). This in turn 
helps increase their interaction. On the other hand, its expression is also elevated in 
melanomas and tumors of the pancreas, breast, lung, prostate and colon (Thornton et al., 
2003), with its expression levels correlated with metastasis (Taniguchi et al., 1992) and 
increased susceptibility to oncogenic transformation (Tatsuka et al., 1992). All these data 
point towards EF1A1 being an emerging key regulator of cell growth, cell death and cell 
dynamics control, the molecular mechanisms of which remain largely unknown.   129
         Our current finding of DLC1 acting in concert  with  EF1A1  via  its interaction with 
SAM domain thus opens up new possible mechanisms that could underlie many aspects of 
DLC1’s   effect   on   anti-metastatic  (Yuan et al., 2003;  Goodison  et al.,  2005),  tumor-
suppression  (Yuan et al., 2003;  Goodison et al., 2005;  Wong et al., 2005;  Zhou et al., 
2004),  or/and  pro-apoptotic functions (Zhou et al., 2004).  Firstly,  when stimulated 
with FGF, there was a concomitant re-localization of EF1A1 to DLC1 at the membrane 
ruffles and not to the focal adhesions, in a process that required the functional SAM 
domain. In the absence of such interactions, most of the EF1A1 was retarded in the 
perinuclear region. These results indicate an intricate control for the interaction between 
EF1A1 and DLC1, depending on the signaling input. Indeed, we further showed that the 
catalytic-inactive mutant of DLC1 did not allow their co-localization in quiescent cells 
unless it was relieved upon FGF treatment. This result supports the functional coupling 
between the SAM and GAP domains of DLC1 whereby inactivation of Rho signaling is 
necessary for the re-localization of DLC1 and EF1A1 together at membrane ruffles 
(Figure 4.1). Interestingly, wild type or FLF mutant of SAM domain could still be 
localized to those structures independent of other functional modules of DLC1. The basis 
for such autonomous translocation remains unknown. Given that these actin-rich 
structures are involved in cell locomotion (Rodriguez et al., 2003), we propose that DLC1 
interaction with EF1A1 at the membrane ruffles could serve to regulate the invasiveness 
and migratory nature of motile cells. Indeed, we later showed that the presence of SAM 
stimulates cell migration by sequestrating EF1A1 from interacting with endogenous 
DLC1. Consistently, SAM mutant devoid of EF1A1-binding fails to recruit EF1A1 to 
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these  actin-rich  sites  where  it  also  fails  to  affect  cell  migration.  Consistently, 
corresponding DLC1  full  length  mutant also becomes less potent in suppressing cell
 migration. Together, we propose a model whereby the primary role of DLC1-SAM is 
to facilitate EF1A1 translocation to the sites of active actin assembly/disassembly in vivo 
during cell motility control (Figure 4.1). Meanwhile, DLC1 was previously reported to 
localize at focal adhesions through the linker region between SAM and RhoGAP domain, 
and it was recently shown to dramatically reduced RhoA activity at the leading edge of 
cellular protrusions (Liao et. al.., 2007; Qian et. al.., 2007; Healy et. al.., 2007). It is worth 
noting that the cellular relocalization of several other proteins, which are also found both 
at the membrane ruffles and at focal adhesions, was indicated as a key regulatory event in 
polarized cell migration (Wonzniak et. al.., 2004). As the effect of DLC1-SAM serves to 
recruit EF1A1 to the membrane periphery and ruffles and help suppressing cell motility, 
such auxiliary effect should ensure better control on DLC1 activity in cell migration 
during physiological conditions. Given that EF1A1 is involved in actin-mediated cell 
morphogenesis in yeast (Gross and Kinzy, 2005; Gross and Kinzy, 2007), our results 
provide the first evidence that EF1A1 is indeed important for cell migration by linking to 
a RhoGAP protein in the mammalian system. 
Secondly, EF1A1 regulates phosphatidylinositol 4,5-bisphosphate via its 
interaction with phospholipase Cγ1 (Chang et al., 2002). Recently, EF1A1 was identified 
as a binding partner of Akt2 (Lau et al., 2006) while the other isoform of EF1A, EF1A2 
was shown to bind and activate phosphatidylinositol 4 kinase (PI4K) and Akt, depending 
on the intracellular abundance of phosphatidylinositol 3,4,5-trisphosphate (Amiri et. al.., 
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2006; Jeganathan and Lee, 2007). In this regards, DLC1 has also been identified to be a 
target for Akt kinase signaling in response to  insulin  (Hers et. al.., 2006)  and  its  rat 
homolog, p122RhoGAP was also shown to interact with phospholipase C  (Homma and 
Emori, 1995; Sekimata et al., 1999; Yamaga et al., 2007), which helps in generating the 
IP3. Based on these findings, it is likely that DLC1 and EF1A1 could act in concert to 
regulate PI(3,4,5)P3/Akt pathway and phosphoinositide metabolism which is necessary 
for cell growth, apoptosis and motility control. Furthermore, as indicated above, EF1A1 
acts to either sensitize or protect against apoptosis and also engage in complexing with 
ZPR1 protein for proliferation. Therefore, interaction between DLC1 and EF1A1 could 
also indirectly serve to modulate the threshold of response simply by sequestering EF1A1 
from their actions during protein synthesis or apoptosis induction. It remains an exciting 
prospect to further investigate just how these possible mechanisms operate and whether 
they are functionally linked. 
Thirdly, the interaction between DLC1 and EF1A1 indicates the crosstalk between 
the EF1A1 signaling and the RhoA signaling pathways. In fact, EF1A1 had been 
implicated in the downstream pathways of the Rho signaling in previous work. In the 
yeast Saccharomyces cerevisiae, EF1A1 was find to interact with Bni1p, which inhibits 
the F-actin binding and bundling activities of EF1A1 (Umikawa et al., 1998). Bni1p is the 
homologue of the mouse mDiaphanous, which is an effector of RhoA important for the 
regulation of actin and focal adhesion dynamics (Fukata et. al., 2003). Furthermore, 
EF1A1 was shown to be phosphorylated in vitro by Rho kinase, another effector for 






found that their interaction play an auxiliary role for the inhibition by DLC1 in cell 
migration. As DLC1 is an upstream regulator of RhoA, the interaction between EF1A1 
and DLC1 suggests that down-regulation on the RhoA signaling by DLC1 might be 
mediated not only through direct negative regulation on RhoA but also through targeting 
its downstream substrate, EF1A1. Our work supports the notion that the RhoA pathway 
crosstalks with the EF1A1 pathway and EF1A1 is a common target of multiple molecules 
in the Rho pathway.  
 
 
      Taken together, our results provide the first evidence that the RhoGAP DLC1 can 
functionally interact with EF1A1 through its SAM domain towards sites of active actin 
assembly/disassembly and is involved in inhibiting cell migration. As DLC1 has been 
shown to exert its inhibition on cell migration at least via its GAP activity, such an 
auxiliary role by SAM could help modulate the actin-based dynamics. The complexity of 
function and regulation on DLC family proteins could now be further addressed by 
simple modularity and then validated in the context of the whole protein. Together with 
other common actions of EF1A1 and DLC1 in phosphoinositide metabolism and their 
ability to regulate apoptosis, it is envisaged that DLC1 could exert multiple levels of 
control over cell growth and cell motility (see model in Figure 4.1). It remains to be 
explored just what functions of each and every module confers towards the entire 




findings implicate that EF1A1 could be a common downstream target in the Rho 
signaling pathway that might participate in the Rho-regulated cytoskeletal reorganization. 





















































































































































































Figure 4.1 Implications of DLC1 and EF1A1 interaction on cell dynamics and cell 
growth control. EF1A1 regulate diverse cellular processes, ranging from 
long-established role in protein synthesis to promoting F-actin bundling and stabilizing 
microtubules, controlling normal cell proliferation, transporting β-actin mRNA, 
conferring susceptibility to or cyto-protection against cell death (please see text for more 
details). EF1A1 also activates phosphatidylinositol-4-kinase (at least in plant) and 
phospholipase Cγ1 to regulate PIP2 and IP3 production, similar to the action of PLCδ1 
activation by DLC1. EF1A1 was found to a binding partner of Akt kinase. DLC1’s rat 
homologue p122RhoGAP is also a target of Akt while the effect on p122’s function is not 
clear. EF1A1 has also been shown to be phosphorylated in vitro by Rho kinase, an 
effector for RhoA, resulting in reduced F-actin bundling. At the present report, we show 
that DLC1-SAM domain EF1A1’s translocation to membrane ruffles with DLC1 only 
after FGF stimulation. Furthemore, such translocation requires Rho to be inactivated by 
DLC1 or when FGF is present. As PIP2 production and actin dynamics are both regulated 
by Rho signaling during cell migration and that cytoskeleton control is linked to 
susceptibility of apoptosis, it is plausible that DLC1 and EF1A1 could act in concert 
through a temporal-spatial control of the actin dynamics in order to exert its 
anti-metastasis or/and its pro-apoptotic functions, whose detailed molecular mechanisms 
require more extensive investigation. PLC, phospholipase C; PI(4)P, 
phosphatidylinositol-4-phopshate; PI(4,5)P2, phosphatidylinositol-4,5-bisphopshate; IP3, 
inositol-3,4,5-triphosphate; PIP3, phosphatidylinositol-3,4,5-bisphopshate; DAG, 
diacylglycerol. 
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 4.4 Implications of DLC1 as a novel BCH domain-interacting partner 
In our study, DLC1 was identified as a novel interacting partner for the BNIP-2 
family. Interestingly, the interaction is specific towards BNIP-2 and BNIP-Sα, but not 
BNIP-H. We also confirmed that such interaction with BNIP-Sα is mediated by its BCH 
domain. Since BNIP-2 has similar domain organization as BNIP-Sα, it is very possible 
that the interaction between DLC1 and BNIP-2 could also be mediated by the BCH 
domain. It is known that BCH domains are crucial for the diverse cellular effects of 
members in the BNIP-2 family (Zhou et al., 2002; Zhou et al., 2005; Zhou et al., 2006; 
Buschdorf et al., 2006). The newly identified interaction between BCH domain and 
DLC1 could shed light on the diverse mechanistic function of BNIP-2 family proteins in 
the complex signaling network inside the cell.  
BCH domain was originally identified as the highly homologous sequence 
between the C-terminus of BNIP-2 and N-terminus of p50-RhoGAP (Low et al., 2000A). 
Later research work demonstrates that BCH domains are protein-protein interaction 
domains, which can mediate homophilic interaction with the same protein and/or 
heterophilic interaction with another BCH-domain containing protein (Low et al., 2000B; 
Zhou et al., 2005; Zhou et al., 2006). Meanwhile, BCH domain was also suggested as 
putative phospholipid-binding domain since it shares low homology with the 
lipid-binding Sec14 domain, though no similar property of BCH domains has been 
reported yet (Low et al., 2000A). Proteins that contain a highly conserved BCH domain 
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in their C-terminus and share high homology to the human BNIP-2 protein are grouped in 
the BNIP-2 family, including BNIP-Sα, BNIP-2 and BNIP-H. Although members in the 
BNIP-2 family share very high homology, they have different and specific functions in 
cell dynamic regulation. For example, BNIP-2 can induce cell elongation and membrane 
protrusions (Zhou et al., 2005). BNIP-H can cause similar cell elongation changes and 
play important roles for normal brain function (Buschdorf et al., 2006). Differently, 
BNIP-Sα can lead to cell rounding and apoptosis eventually (Zhou et al., 2002; Zhou et 
al., 2006).  
Recently, our group found that the BCH domains of BNIP-2 family proteins were 
able to target specific small Rho GTPases. Our coworkers show that the BCH domains of 
BNIP-Sα and BNIP-2 can bind to RhoA and Cdc42, respectively (Zhou et al., 2006; Zhou 
et al., 2005) while no interaction was found for BNIP-H towards RhoA, Cdc42 and Rac1 
(Unpublished data of our group courtesy of Chew Li Li). Our group also found that the 
involvement of the different Rho GTPase pathways is required for the different cellular 
functions of BNIP-2 family proteins. BNIP-Sα can activate RhoA that lead to the 
apoptotic effect of BNIP-Sα (Zhou et al., 2006). For BNIP-2, although it won’t affect the 
net Cdc42 GTPase activity in vivo, the functional Cdc42 pathway is necessary for the 
morphological changes induced by BNIP-2 (Zhou et al., 2005). Since RhoA and Cdc42 
are also the targets of DLC1 (Wong et al., 2003), the interaction between DLC1 and 
BNIP-2/BNIP-Sα indicates that the mechanism under the diverse functions of BNIP-2 
family could be a cellular process with multiple-step control of different Rho GTPase 
pathways. BNIP-2 family members might exert their cellular effects not only by directly 
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binding and/or activating small Rho GTPases, but also through interaction with the 
regulator of Rho GTPases, DLC1. Since activate RhoA signaling is necessary for the 
apoptotic function of BNIP-Sα (Zhou et al., 2006), the binding of BNIP-Sα to DLC1 may 
provide several effects: First, it might abolish the affinity of DLC1 towards RhoA, thus 
releasing RhoA from its negative regulator DLC1. As a result, RhoA could be free for the 
binding and activation by BNIP-Sα. Alternatively, BNIP-Sα might form a complex with 
DLC1 and RhoA together. Here DLC1 might act as a targeting signal instead. Their 
physiological interaction relationship and the underlying mechanistic function needs 
further detailed investigation including binding studies and functional assays. 
 
4.5 The molecular mechanism of the interaction between DLC1 and BNIP-Sα  
Our studies delineate three distinct regions on DLC1, i.e. DLC1-P1, -P3 regions 
and START domain, for the interaction with BNIP-Sα. We also confirmed that BNIP-Sα 
interacts with DLC1 through its BCH domain. Our findings in such regions may shed 
light on some possible mechanisms of how other modules besides the RhoGAP domain 
could contribute to the entire function and regulation of DLC1 protein. 
DLC1-P1 and P3 regions are within the long sequence (around 600 amino-acid 
long) between the SAM domain and the GAP domain of DLC1. Although no conserved 
domain could be identified in such a long sequence, corresponding regions of this 
sequence are conserved with around 30-40% identity among the three human DLC 
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homologues, DLC1, DLC2 and DLC3 (Durkin et al., 2007), which indicates the presence 
of unknown motif(s) in it. Thus we hypothesized that this sequence might play a role in 
the function of DLC1. Several recent founding supports our hypothesis by revealing some 
functional motifs within this sequence. Serine 322 of the DLC1 rat homologue 
p122RhoGAP (corresponding to the serine 329 within the P1 region of DLC1) was found 
to be phosphorylated by Akt upon insulin stimulation, which was suggested as a 
regulatory module by growth factors for its GAP activity towards Rho GTPases (Hers et 
al., 2006). Another two residues serine 440 and tyrosine 442 (located between P1 and P3 
region) could interact with the tensin family proteins that help locating DLC1 to focal 
adhesions. Such interaction and localization is essential to the suppressive function of 
DLC1 in colony formation and cell growth (Qian et al., 2007; Liao et al., 2007). Our 
novel identified interactive activity of DLC1-P1 and -P3 regions towards BNIP-Sα could 
also implicate the functional significance of this region. At the same time, it remains to be 
deciphered how DLC1-P1/P3 could have affinity towards BNIP-Sα and whether they 
could similarly interact with other BCH domain containing proteins. In our direct binding 
studies, we already confirmed the direct and specific binding affinity of P3 region to 
BNIP-Sα full length and its BCH domain, while whether the interaction between 
DLC1-P1 and BNIP-Sα is direct or not remains to be elucidated by future research. 
Interestingly, we also show that deletion in the P3 region lead to the lost of function of 
DLC1 protein, indicating the functional importance of DLC1-P3. Whether there is any 
special motif in P3 region that mediates the interaction with BNIP-Sα BCH domain and 
whether such interaction confers to the functional importance of DLC1-P3 needs further 
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binding and functional studies combined with bioinformatic prediction.  
We also show that there is binding affinity between the START domain of DLC1 
and BNIP-Sα BCH domain. Work done by our co-worker show that DLC1-START 
domain could not bind to BNIP-Sα full length and BCH domain in in vitro direct binding 
studies (courtesy of Teo Ai Shi, Valerie). We speculate that the interaction between 
START domain of DLC1 and BNIP-Sα might be mediated by a third partner in vivo. 
Lipid could possibly mediate their interaction, since START domain and BCH domain are 
both putative lipid-binding domains. The START domain family has long been 
recognized as lipid-binding domain. The lipid-binding property of many START domains 
has already been demonstrated, such as cholesterol-binding by the START domains of 
STARD1 and MLN64, phophatidycholine-binding by the START domain of PCTP (Alpy 
and Tomasetto, 2005). Some of the functions from such lipid-binding property have also 
been shown in lipid trafficking, lipid metabolism, lipid-modulated signal transduction and 
transcriptional regulation (Alpy and Tomasetto, 2005). There is some evidence 
implicating the lipid-binding property of DLC1-START domain. An auxiliary role of the 
START domain of DLC1 rat homologue p122RhoGAP was suggested in its specific lipid 
raft caveola-localization, which is involved in cholesterol trafficking and Ca2+ 
mobilization (Yamaga et al., 2004). A role of DLC1-START domain was also implicated 
in lipid-regulated pathway, since DLC1 had been identified as a binding partner of PLCδ1 
and C-terminus half of DLC1 containing START domain is responsible for the activation 
of PLCδ1 by DLC1 (Homma and Emori, 1995; Sekimata et al., 1999). Recently, it was 
shown that DLC1 could interact with PLCδ1 through the pleckstrin homology (PH) 
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domain, which binds PI(4,5)P2, the phospholipid substrate of PLCδ1, with high affinity 
(Yamaga et al., 2007). Such finding indicates that DLC1-START domain might interact 
with lipids esp. phospholipid. BCH domains of BNIP-2 family proteins might also have 
affinity towards phospholipids, since they share low degree of sequence homology to the 
phospholipid-binding Sec14 domain (Low et al., 2000A) though there is no evidence to 
indicate lipid-interaction nature of any BCH domain yet. Our data showing the possibly 
indirect binding of DLC1-START and BNIP-Sα-BCH domains raises the possibility that 
phospholipids might help bring the two domains into proximity inside the cells, and lipid 
signals could regulate the functions of DLC1 and BNIP-Sα through modifying their 
interaction. At the same time, it remains to be explored whether the interaction between 
DLC1-START and BNIP-Sα-BCH domains could affect the affinity of DLC1-P1/P3 
regions towards BNIP-Sα under physiological conditions. In future work, it will be 
interesting to investigate whether there is any lipid binding property of the START 
domain of DLC1, whether such property could regulate the function of DLC1 and how 
this is related to the interaction with BNIP-Sα.  
 
4.6 Functional implications of DLC1 interacting with BNIP-Sα 
BNIP-Sα is a pro-apoptotic protein (Zhou et al., 2002). Work of our co-worker 
revealed that BNIP-Sα could bind to RhoA and trigger apoptosis by activating it (Zhou et 
al., 2002; Zhou et al., 2006). At the same time, BNIP-Sα could interact with a negative 
regulator of RhoA, p50-RhoGAP, and prevent p50-RhoGAP from inactivating RhoA. As 
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a result, BNIP-Sα suppresses p50-RhoGAP effects on cell protrusions while promoting 
cell rounding through its interaction with RhoA. Here, we demonstrate that BNIP-Sα 
could interact with DLC1, another RhoGAP of RhoA. Our finding implicates that 
BNIP-Sα might exert its cellular effect through interaction with multiple RhoGAPs.  
Although DLC1 itself could also induce apoptosis (Wong et al., 2005; Zhou et al., 
2004; Syed et al., 2005), its interaction with BNIP-Sα is not contradictory to the 
proapoptotic function of each of the proteins. Apoptosis induced by DLC1 involves the 
activated caspase-3 pathway. But such effect was only present in the cancerous cell lines 
without endogenous DLC1 expression, not in the nontumorigenic cell line with similar 
origin (Zhou et al., 2004; Syed et al., 2005). This shows that the proapoptotic effect of 
DLC1 could be cell type-specific. In comparison, BNIP-Sα-induced apoptosis is not cell 
type-specific and could be caspase-independent (Zhou et al., 2002; Zhou et al., 2006). 
Together, it shows that DLC1 and BNIP-Sα use different mechanisms to induce apoptosis. 
The interaction of BNIP-Sα and DLC1 could be a regulatory step on RhoGAPs in the 
apoptosis process triggered by BNIP-Sα.  
Both BNIP-Sα and DLC1 can induce apoptosis and target RhoA, a key 
cytoskeleton regulator (Zhou et al., 2002; Zhou et al., 2006). Previously, it was known 
that apoptosis can lead to cytoskeleton changes eventually. Now more and more findings 
show that cytoskeleton changes can also be a regulatory step of apoptosis. Recently, 
RhoA was known to be important in the regulation of various apoptosis processes. The 
regulation of apoptosis by RhoA could be achieved either through its down-regulation or 
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up-regulation under different cellular conditions. For example, down-regulation of RhoA 
was shown to induce apoptosis in epithelianl cells (Fiorentini et al., 1998), fibroblasts 
(Bobak et al., 1997), lymphoma cells (Moorman et al., 1999), endothelial cells 
(Hippenstiel et al., 2002), osteosarcoma cells (Fromigué et al., 2006) etc. Meanwhile, 
up-regulation of RhoA was reported to lead to apoptosis in some other cell types, such as 
phorbol ester-stimulated erythroblastic cell lines (Chang and Lee, 2006), fibroblasts 
induced by cellular cholesterol depletion (Calleros et al., 2006), cardiomyocytes (Del Re 
et al., 2007), and neurons treated with phenylalanine (Zhang et al., 2007). The expression 
of RhoA could promote apoptosis in zebrafish embryogenesis as shown by the work of 
our co-worker (Zhu et al., 2007). Altogether, these data demonstrates that a balanced 
cellular level of RhoA activity is essential for cell fate. As DLC1 can induce apoptosis 
and down-regulate RhoA, and BNIP-Sα can activate RhoA to induce apoptosis, our 
newly identified interaction between DLC1 and BNIP-Sα further supports the notion that 
the balance of RhoA activity in cell is crucial to cell survival. For future research, it would 
be interesting to further investigate the interaction mechanistic model of BNIP-Sα and 
DLC1, the regulation on RhoA by such interaction, and the downstream cellular effects. 
 
4.7 DLC1-P3 region is a novel regulatory module for the function of DLC1 
Our work identified DLC1-P3 region as a novel important region for the function 
of DLC1. We show that deletion in P3 region abrogates the ability of DLC1 in causing 
cell rounding and dissociation of stress fibers and focal adhesions, and lowers the 
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capacity of DLC1 in suppressing cell migration while not affecting the in vivo GAP 
activity of DLC1 towards RhoA. Most RhoGAPs contain multiple domains and they 
carry out their functions by integrating several signaling pathways through these 
functional modules. Currently, bioinformatic search shows no obvious motif within the 
P3 region to predict its functional mechanism. It raises an intriguing question about how 
DLC1-P3 region can play a role to the function of DLC1.  
Protein/lipid interaction mediated by DLC1-P3 region could be one possible 
mechanism that leads to its role in the function of DLC1. Many RhoGAPs can interact 
with other proteins to mediate their functions (Tcherkezian and Lamarche-Vane, 2007). 
For example, our group has shown that the interaction between cortactin, a cortical actin 
binding protein and the proline-rich region of BPGAP1 is essential for the function of 
BPGAP1 in promoting cell migration (Lua and Low, 2004). Some RhoGAPs can also be 
directly regulated by lipid-binding (Tcherkezian and Lamarche-Vane, 2007). For example, 
β2-chimaerin, a GAP for Rac, can bind to the lipid second messenger DAG 
(diacylglycerol) that facilitates its RacGAP function by localizing β2-chimaerin to the 
plasma membrane site of active Rac1 (Wang and Kazanietz, 2006). In our current studies, 
we have identified the direct binding activity of DLC1-P3 region and the BNIP-Sα-BCH 
domain. It is possible that P3 region might regulate the function of DLC1 by integrating 
the BNIP-Sα signaling pathway with the Rho GTPase pathway. Given that BCH domain 
is a putative lipid-binding domain, interaction between DLC1-P3 and BNIP-Sα might 
facilitate the function of DLC1 by targeting it to the lipid rafts where active Rho GTPases 
are located.  
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Phosphorylation could be another possible regulatory mechanism for DLC1 by its 
P3 region. Many RhoGAPs can be regulated by phosphorylation which can affect the 
translocalization or protein-binding of the RhoGAPs and lead to either activation or 
inhibition of their functions (Tcherkezian and Lamarche-Vane, 2007). Our current studies 
show that deletion in DLC1-P3 region leads to the localization of DLC1 in large vascular 
structures instead of diffused localization. It raises the possibility that there might be 
some phosphorylation sites in the P3 region that affects the intracellular trafficking the 
DLC1 protein. Bioinformatic tools (such as Netphos 2.0 Server, 
http://www.cbs.dtu.dk/services/NetPhos/) identified several putative phosphorylation sites 
in P3 region (Figure 4.2). It remains to be elucidated whether these putative sites in 
DLC1-P3 region are phosphorylated and what is the regulation on DLC1 by such 
phosphorylation.  
 
WSEKFSDEGDSDSALDSVSPCPSSPKQIHLDVDNDRTTPSDLDSTGNSLNEPEEPSEIPERRDSGVGASLTRSNR     560 
HRLRWHSFQSSHRPSLNSVSLQINCQSVAQMNLLQKYSLLKLTALLEKYTPSNKHGFSWAVPKFMKRIKVPDYKDRSVFG     640 
VPLTVNVQRTGQ                                                                         652 
.S...S....S.S.....S....S.............T.S...S...S.......S.......S...........     560 
......S...S...S.........................................................Y...S...     640 
............                                                                         652 
Phosphorylation sites predicted: Ser: 15 Thr: 1 Tyr: 1 
Figure 4.2 Putative phosphorylation sites in DLC1-P3 region. Putative 
phosphorylation sites in DLC1-P3 region (corresponding to amino acid 485-652 in the 
sequence of DLC1) are predicted using Netphos 2.0 Server 
(http://www.cbs.dtu.dk/services/NetPhos/). 
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Earlier work on DLC1 or its rat homologue p122RhoGAP had only investigated 
their GAP activities towards RhoA, Cdc42 and Rac1 through in vitro GAP assays 
(Homma and Emori, 1995; Wong et al., 2003). Our data show that deletion in DLC1-P3 
region does not affect its in vivo GAP activity towards RhoA. Meanwhile, we can not rule 
out the possibility that P3 region could directly regulate the GAP activity of DLC1 on 
other Rho GTPases. Very recently, DLC1 was shown to downregulate RhoB and RhoC as 
well as RhoA and Cdc42 in vitro (Healy et al., 2007). DLC1-P3 might play a role in the 
function of DLC1 through regulating its GAP activity towards RhoB or RhoC instead. 
Although RhoA, RhoB and RhoC share 85% identity on amino acid sequence, they have 
distinct cellular functions in the regulating cytoskeleton and cell motility, development 
and transcription (Wheeler and Ridley, 2004). RhoA plays a key role in controlling cell 
contractility. RhoB is important for the regulation of cytokine trafficking and cell survival. 
RhoC was shown to be important in cell locomotion. Besides, their patterns of altered 
expression and activity in cancers are very different. In cancers, RhoA and RhoC were 
found to be overexpressed especially in highly metastatic cancer cell lines. While RhoA 
can promote transformation in fibroblasts, RhoC doesn’t have similar effect but it can 
promote metastasis. In contrast, the expression of RhoB was found to be decreased in 
more progressed cancers. Furthermore, RhoB can inhibit migration, invasion and 
metastasis. The different cellular roles of RhoA, RhoB and RhoC attribute to the binding 
specificity of their regulators and effectors, which is achieved through either different 
binding affinity or different cellular localization. Given that many RhoGAPs have 
different in vivo specificity of RhoGTPases from their in vitro activity, DLC1 might have 
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different specificity towards RhoA, RhoB and RhoC in vivo, though DLC1 was shown to 
have similar in vitro affinity towards them (Healy et al., 2007). Since deletion in P3 
region leads to the localization of DLC1 in large vascular structures in the cytosol instead 
of diffused localization in the cytosol in most of the cells, DLC1-P3 region might regulate 
the intracellular trafficking of DLC1 which would affect its in vivo RhoGAP activity 
towards RhoB/RhoC and affect the functions of DLC1 in regulating cell morphology and 
cell migration.  
 
4.8 Conclusions and future perspectives 
In this study, we have identified EF1A1 as a novel interacting partner for the SAM 
domain of DLC1, defined their interaction mechanism through identifying important 
motif/domain involved for their interaction and investigated the functional significance of 
their interaction in cell migration. Significantly, we have shown that hydrophobic residues 
F38 and L39 in DLC1-SAM form an indispensable interacting motif for the interaction 
with EF1A1. Using DLC1 mutants mutated at these residues, we demonstrated that SAM 
domain is necessary for DLC1 to translocate EF1A1 to the membrane periphery and 
ruffles upon fibroblast growth factor stimulation, and it acts as an auxiliary switch to the 
anti-metastastic RhoGAP domain. 
We have also identified BNIP-Sα as another novel interacting partner for DLC1. 
We have shown that BNIP-Sα interacts with DLC1 through its BCH domain and the 
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GAP-binding motif within the BCH domain is essential for their interaction. On DLC1, 
multiple sites showed interaction affinity,  including the P1, P3 regions and the START 
domain. Additionally, we have found that the P3 region is important for the function of 
DLC1 to change cell morphology and suppress cell migration, while not affecting the 
RhoGAP activity of DLC1. 
The findings shown in this study have raised some interesting issues.  
What signaling pathway is involved in the interaction of DLC1 and EF1A1 that 
help suppress cell migration? 
Our data demonstrate that DLC1-SAM recruits EF1A1 to membrane periphery 
and ruffles and plays an auxiliary role in the suppression of cell migration by DLC1 while 
the mutant devoid of the binding with EF1A1 does not have such effects. It shows that the 
auxiliary effect of DLC1-SAM is mediated by its interaction of DLC1 with EF1A1 and 
the translocalization of EF1A1 to cell periphery. It is possible that the presence of SAM 
stimulates cell migration by sequestrating EF1A1 from interacting with endogenous 
DLC1. It implicates that not only the translocalization of EF1A1 but also an unknown 
signaling pathway coupled by the interaction of EF1A1 and DLC1 at cell periphery is 
necessary to modulate the function of DLC1 in migration. For future study, it would be 
interesting to investigate the signaling molecules downstream of the binding of DLC1 
with EF1A1. The phospholipase C pathway might be the target coupled by DLC1 and 
EF1A1 (Figure 4.1). Previous research shows that EF1A1 binds to the split-Pleckstrin 
Homology (PH) domain of phospholipase C (PLC) γ1 isoform to regulate IP3 production 
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(Chang et al., 2002), while its interaction activity towards other PLC isoforms has not 
been tested. Studies on DLC1 show that DLC1 rat homologue p122RhoGAP can 
specifically bind to the PH domain of PLCδ1 isoform but not PLCβ1 or PLCγ1 and 
activate PLCδ1 (Homma and Emori, 1995; Sekimata et al., 1999; Yamaga et al., 2007). 
PLC is a key molecule in the lipid metabolite signaling. Its PH domain is essential for its 
localization at plasma membrane where activated PLC hydrolyzes inositol phospholipid 
to generate two important lipid second messengers, diacylglycerol (DAG) and IP3. 
Recently, PLCδ1 was found to be a novel tumor suppressor that could inhibit tumor 
growth and cell migration (Fu et al., 2007). Based on these findings, PLCδ1 could be the 
target downstream of the interaction of DLC1 and EF1A1 at cell periphery to regulate 
cellular activities especially cell growth and migration. To address this issue, biochemical 
assays of the activity of PLC in the presence of DLC1 and EF1A1 and functional studies of 
DLC1 using PLC pathway inhibitors could be carried out. 
 
Does the interaction between DLC1 and EF1A1 also play a role in other cellular 
activities besides migration, such as cell growth, apoptosis and embryonic development, 
which is non-compensable by DLC1 homologues?  
Previous research on DLC1 mainly focused on its tumor suppressor function 
while the role of DLC1 under physiological conditions in normal cellular activites has not 
been addressed. Recent finding with DLC1 knockout mice shows that homozygous DLC1 
deletion is lethal to embryo development (Durkin et al., 2005). It indicates that DLC1 
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also play other important cellular roles besides tumor suppression. Further more, the 
mouse orthologues for DLC2 and DLC3 have been identified (Durkin et al., 2007B), 
implying that the functions of DLC2 and DLC3 can not compensate the functions of 
DLC1 or probably their expression profiles are different though they have very similar 
roles in tumor suppression. In our current study, we identified EF1A1 as a novel partner 
of DLC1, showing the role of their interaction in the regulation of cell migration. We 
further showed that the homologous DLC2-SAM could not interact with EF1A1 and did 
not have any of such effects. Given that EF1A1 is a central regulator for a variety of cell 
activities which is not confined to protein synthesis (as introduced previously in this 
chapter), its interaction with DLC1 could also regulate other cellular processes which 
could contribute to the specific functions of DLC1 compared with its homologues. 
Functional assays on cell growth, apoptosis, actin and microtubule dynamics, and 
embryonic development can be the focus for further investigation. DLC1 and its mutant 
devoid of EF1A1-interaction could also be used in these functional assays. For future 
studies, the in vivo molecular property of the proteins could be better studied under 
physiological conditions. Technique such as small interfering RNAs (RNAi) may be used 
to knock-down the expression of EF1A1 and DLC1 to investigate the cellular function of 
their interaction when these two proteins are lowly expressed. Zebrafish, a good animal 
model for development research, can also be used. Currently, DLC1 homologues in 
zebrafish are under investigation in our group. In future studies of DLC1, we can utilize 
the morpholino, tissue-specific and inducible knockdown/expression techniques in 
zebrafish. We have recently successfully employed such strategy to investigate the role of 
 150
RhoA to apoptosis in zebrafish embryogenesis (Zhu et al., 2007). Significantly, it 
provides an excellent alternative to avoid lethal effect of DLC1 deletion in embryo 
development. 
 
What is the function of the interaction between DLC1 and BNIP-Sα/BNIP-2? 
Our current work have also identified BNIP-Sα and BNIP-2 as novel interacting 
partners for DLC1. It remains to be explored just what functions of such interactions 
confer towards the entire function and regulation of DLC1 protein. For BNIP-Sα, we 
have shown that the GAP-binding motif within its RhoA-binding region is essential for 
the binding with DLC1. Our group has previously shown that BNIP-Sα mediates 
apoptosis through the binding and activation of RhoA by displacing p50RhoGAP (Zhou 
et al., 2002; Zhou et al., 2006). Since RhoA is also a target of DLC1, it would be 
interesting to elucidate the interactive and functional relationship of BNIP-Sα, DLC1 and 
RhoA. Further binding studies for these three proteins and apoptosis assays could be 
carried out for future investigation. Further more, as both BNIP-Sα and DLC1 contain 
potential lipid-binding domains, i.e. BCH domain and START domain respectively, it 
remains to be seen whether lipid metabolites could affect their functions through 
regulating their interaction. For BNIP-2, we had only identified its interactive activity 
with  DLC1.  More  binding  studies are needed to explore their  interaction mechanism. 
Work on BNIP-2 by our colleagues shows that it can induce cell elongation and 
membrane protrusions through the interaction with Cdc42 (Zhou et al., 2005). Since 
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Cdc42 is also the target of DLC1 and DLC1 is a regulator of cell migration which 
involves actin-disassembly and cell morphological changes, the interaction of DLC1 and 
BNIP-2 raise an interesting question on whether their interaction could impact on the 
inhibitory effect of DLC1 in migration. Proper migration activity is also an essential 
process during embryonic development. Currently, BNIP-2 and DLC1 homologues in 
zebrafish are under investigation in our lab. Migration assays on cellular level and in 
zebrafish embryogenesis could be used for future research to explore the functional 
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